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Background: Women with previous cervical surgery are at an increased risk of preterm birth 
(PTB) and this risk is present in all pregnancies thereafter. PTB remains the leading cause of 
neonatal morbidity and mortality. Interventions to prevent preterm birth are vaginal cerclage, 
vaginal progesterone and the Arabin pessary, indicated in women with cervical surgery with 
a mid-trimester cervical length <25mm between 16-24 weeks of gestation. It is unknown 
which intervention has the greatest efficacy in preventing PTB in this cohort.  
Methods: This thesis systematically reviewed the literature surrounding the management of 
women with a previous LLETZ or knife cone biopsy. We performed searches within Scopus, 
Pubmed and Cinahl databases to identify any observational studies or randomised 
controlled trials comparing either progesterone, vaginal cerclage or Arabin pessary to a 
control or comparator group. Two independent review authors screened papers for inclusion 
and assessed risk of bias, cases of uncertainty were discussed with a third review author. 
The GRADE approach was used for quality assessment. A retrospective cohort study was 
conducted of all women with prior cervical surgery attending the specialist PTB prevention 
clinic at Liverpool Women’s hospital between 2008-2020. Exclusions were made for women 
presenting more than once within the study period, missing data, transabdominal cerclage, 
radical trachelectomy and laser procedures. Data were analysed using univariable and 
multivariable generalised linear models in R (Version 3). Separate models were performed 
for women with and without a previous spontaneous preterm birth. 
Results: We identified 6 studies eligible for inclusion in the systematic review. There was 
insufficient evidence to draw conclusions for progesterone or pessary. Studies demonstrated 
no evidence to support the use of cerclage in women with previous cervical surgery. Our 
cohort study identified 441 patients for analysis, which demonstrated no statistically 
significant association between vaginal cerclage or Arabin pessary and gestation time. 
Progesterone was associated with a decrease in gestation time (Est -3.15 (1.059); p-value 
0.004) in women with a previous sPTB. 
Conclusion: The systematic review yielded no studies comparing the efficacy of cerclage, 
pessary and progesterone to one another. Studies of cerclage found no additional benefit of 
its use in women with previous cervical surgery. These findings are supported by the 
findings of the retrospective cohort study. Vaginal cerclage, vaginal progesterone and the 
Arabin pessary, that are effective in other high-risk cohorts, do not present the same efficacy 
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CHAPTER 1: INTRODUCTION 
1.1 PRETERM BIRTH 
 
Preterm birth (PTB) is defined as delivery of the child prior to 37 weeks of gestation. It 
affects around 10.6% of pregnancies, equating to approximately 15 million PTBs per year 
globally, though incidence differs per country1. It can be categorised into extreme preterm 
(<28 weeks), very preterm (28-32 weeks), moderate preterm (32-33+6 weeks) and late PTB 
(34-36+6 weeks)2. PTB can occur either following spontaneous labour or secondary to 
medical intervention (iatrogenic) for maternal factors such as placental compromise or fetal 
factors including intrauterine growth restriction and fetal distress3. Conversely, the aetiology 
of spontaneous preterm birth (sPTB) is multifactorial with age, ethnicity, BMI, smoking, 
socioeconomic status and number of fetuses all contributing to risk4. Previous history of PTB 
and prior excisional treatments of the cervix for cervical intraepithelial neoplasia (CIN) also 
confer an increased risk of PTB5, 6. In singletons, a previous sPTB is the best predictor of a 
subsequent PTB, and it is associated with a 5.6-fold increased risk of sPTB in future 
pregnancies7.  
Preterm delivery remains the principal cause of neonatal morbidity and mortality worldwide8. 
There is an inverse association between gestation at delivery and the occurrence of adverse 
neonatal outcomes9, such as retinopathy of prematurity, sepsis, necrotising enterocolitis, 
bronchopulmonary dysplasia and intraventricular haemorrhage10. These conditions are 
associated with long-term morbidity including cognitive, hearing and visual impairments, 
especially in infants delivered between 30-34 weeks11. There is also a greater risk of severe 
cognitive impairment associated with earlier gestations at delivery11. PTB can indicate the 
need for a neonatal intensive care unit (NICU) admission and the requirement for further 
interventions such as ventilation, phototherapy, antibiotics and parenteral feeding. Length of 
hospital stay for preterm infants decreases with increasing gestational age at delivery. This 
highlights the importance of interventions to prolong pregnancy in high-risk groups to 
optimise neonatal outcomes, reduce the need for prolonged NICU admission and decrease 
the long-term health, social and economic burden resulting from the conditions associated 
with PTB. 
1.2 THE CERVIX 
 
The cervix is a mechanical structure which retains the fetus in utero during pregnancy, and 
acts as a barrier to infective organisms. The main components of the cervical stroma are 
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fibroblasts and smooth muscle cells that secrete extracellular matrix (ECM), largely 
composed of collagen, proteoglycans and elastic fibres. The mechanical strength of the 
cervix corresponds to the composition of the ECM, this changes throughout pregnancy and 
labour in response to levels of oestrogen and progesterone12. Maintenance of pregnancy 
requires a high progesterone and low oestrogen level, whereas cervical ripening for 
parturition occurs in response to a low progesterone and high oestrogen level12. Both 
oestrogen and progesterone levels are regulated by the expression of 17β-hydroxysteroid 
dehydrogenase type 2 in the endocervical epithelium13. The cervix remodels continuously 
and collagen becomes more disorganised with advancing gestation. This alters the role of 
the cervix allowing it to act as both a barrier to retain the fetus throughout pregnancy, and as 
a passage for delivery during labour12. CL decreases progressively from mid-pregnancy until 
delivery14. The downregulation of 17β-hydroxysteroid dehydrogenase type 2 results in a 
decrease in progesterone and increase in oestrogen concentration to create the ideal 
microenvironment for cervical ripening in preparation for parturition13. Should this process 
occur prematurely, CL may decrease below 20mm which is associated with an increased 
likelihood of PTB2. The National Institute for Health and Care Excellence (NICE) provides 
regular guidance updates for investigating and managing a variety of medical conditions. 
Their guidance on the management of PTB recommends mid-trimester ultrasound screening 
of CL in women at risk of PTB. NICE guidance uses CL <25mm as the threshold for offering 
preventative intervention, in line with the 10th percentile and a relative risk of PTB of 3.315, 16. 
Mid-trimester CL screening in high-risk women has enabled the identification of cervical 
shortening at an earlier gestation and consequently the prediction and opportunity for 
intervention to prevent PTB. 
1.3 CERVICAL INTRAEPITHELIAL NEOPLASIA   
 
Cervical intraepithelial neoplasia (CIN) is a pre-malignant abnormal growth of squamous 
cells in the transformation zone of the cervix, graded from mild (CIN1) to severe (CIN3). 
Human papillomavirus (HPV) infection increases the risk of CIN, with subtypes 16 and 18 
accounting for the majority of cases worldwide. Those at the greatest risk of HPV infection 
are sexually active women under 3017. The rates of HPV in the United Kingdom (UK) have 
significantly reduced following the introduction of the HPV vaccination programme in 2008. 
The HPV vaccine provides protection against the two most common subtypes, HPV 16 and 
18, of which the prevalence has decreased from 8.2% to 1.6% in 16-18 year olds, as of 
201618. Progression of CIN to squamous carcinoma can occur though the likelihood has 
reduced as a result of the national cervical screening programme, allowing for early 
identification and excision of lesions. Lesions of the cervix alone, when untreated, are 
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thought to increase the risk of PTB in subsequent pregnancies and excisional treatments 
further increase that risk19. Notably, a 2009 study demonstrated the occurrence of sPTB in 
11% of patients with untreated CIN3 relative to only 6% in the general population20. 
1.4 CERVICAL EXCISION 
 
Treatment for moderate-severe CIN commonly involves cervical excision. These treatments 
allow for quick and effective intervention, often with precise margins, and the scope for 
histological analysis of removed cervical tissue post-excision. The main methods of excision 
are cold knife cone biopsy (KCB), large loop excision of the transformation zone (LLETZ) 
and radical trachelectomy. KCB and LLETZ are less invasive options than radical 
trachelectomy, which can be advantageous for women of child-bearing age17. However, all 
of these procedures carry their own risks of adverse effects. There is a significant 
association between excisional procedures of the cervix and the incidence of PTB, and 2.5% 
of UK PTBs per year are estimated to be a direct result of excisional procedures21. Cervical 
excision and incidental short CL are both independently associated with PTB6, though 
studies and clinical guidance often group these two risk factors. The precise mechanism 
linking excisional treatments of the cervix to the risk of PTB is unknown. Theories include the 
presence of ascending vaginal infection and the weakening effects of cervical regeneration 
post-excision22. Excisional procedures of the cervix remove the glands that secrete 
components of the mucus plug, that normally acts as a chemical and physical barrier to 
infection23. Without the mucus plug, the risk of ascending infection is increased and as a 
result, so is the risk of PTB. An alternate theory suggests that following excision, the tissue 
rapidly regenerates, altering the collagen arrangement and weakening the quality of the 
regenerated tissue24, resulting in an increased risk of PTB. 
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 KNIFE CONE BIOPSY  
 
KCB is a technique used in the treatment of CIN grades 2 or 3 (Figure 1), usually performed 
under general anaesthesia. The borders of cervical tissue to be excised are directed by 
colposcopy findings, allowing for clear margins. The procedure involves visualisation of the 
cervix using a right-angle retractor, followed by the excision of the cervix starting outside the 
transformation zone using an angled blade. Mayo scissors are then used to excise the base 
of the cone and a Kevorkian curette is used to remove the remaining endocervical canal25. 
KCB has been associated with perioperative infection risk, cervical stenosis, post-operative 
bleeding and the potential risk of PTB and perinatal mortality in subsequent pregnancies26. 
The depth of the cone is directly related to the risk of PTB, with greater depth conferring a 
higher risk22. A case control study demonstrated that risk of PTB increases linearly with 
depth of tissue removed beyond 9mm, although excision of less than 9mm of tissue 
represents no increased risk beyond that of the background population27. This leads to 
debate in the management of patients undergoing KCB in order to appropriately balance 
both their oncological and obstetric risks. Premature pre-labour rupture of membranes 
(PPROM) has also been linked to prior cold knife conisation of the cervix28 and further 
studies have reported the increased risk of perinatal mortality associated with conisation29.  
Figure 1: Knife cone biopsy 
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 LARGE LOOP EXCISION OF THE TRANSFORMATION ZONE  
 
Large loop excision of the transformation zone (LLETZ), also termed loop electrosurgical 
excision procedure (LEEP), involves the application of an electrical current through a wire 
loop electrode to produce a combined excisional and coagulation effect (Figure 2). The 
depth of tissue removed is typically less than that of a KCB and LLETZ procedures can be 
performed under local anaesthetic26. Though they are generally regarded as low risk of 
morbidity, studies have noted the presence of side effects including abdominal pain, vaginal 
bleeding and post-LLETZ cervical stenosis30. A 2013 Cochrane review comparing the 
effectiveness of surgical interventions for CIN, determined no statistically significant 
difference in the risk of vaginal bleeding, post-procedure cervical stenosis and residual 
disease between KCB and LLETZ procedures17. Similarly to cone biopsy, LLETZ has been 
linked to an increased risk of PTB, though many studies describe LLETZ as a safer 
alternative to KCB as it carries a lower risk of PTB19 This is likely owed to the lesser volume 
of cervical tissue removed during a LLETZ procedure relative to that of a KCB. The depth of 
tissue excised during a LLETZ procedure directly corresponds to the risk of PTB, therefore it 
is logical that the greatest risk of PTB is more commonly seen following multiple LLETZ 
procedures as opposed to a single LLETZ31. Further to this, the risk of PTB applies not only 
to the first post-excisional pregnancy but to all subsequent pregnancies thereafter32. The 
interval from LLETZ procedure to pregnancy and its impact on PTB has been discussed in 
various studies and several studies have reported no significant difference in the incidence 
of PTB irrespective of the time interval between cervical excision and conception27, 33, 34. It 
can be concluded that the risk of PTB does not decrease with an increase in time interval 
from the procedure.  
Figure 2: Large loop excision of the transformation zone 
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 RADICAL TRACHELECTOMY  
 
Radical trachelectomy involves the removal of the cervix, the superior portion of the vagina 
and the parametrium, and often incorporates the surrounding lymph nodes. This technique is 
more invasive than KCB and LLETZ procedures and is performed either vaginally or 
abdominally. The vaginal approach is composed of a laparoscopic phase to perform a pelvic 
lymphadenectomy followed by a vaginal phase. The abdominal approach involves more 
radical parametrial and paracervical resection than the vaginal approach. A cervico-isthmic 
cerclage is often placed at the end of the procedure35. Complications of the procedure 
include ureteral injuries, peritonitis and the formation of urinary tract fistulae36. Radical 
trachelectomy also increases the risk of PTB, threatened PTB, premature rupture of 
membranes and second trimester miscarriage in any subsequent pregnancies35. It has been 
hypothesised that the excisional procedure causes disruption to the mechanical structure of 
the cervix. This causes an increased susceptibility to ascending infection, and the resulting 
inflammatory processes can lead to PTB37.  
1.5 PREDICTING PRETERM BIRTH 
 
Spontaneous preterm birth is multifactorial and the prediction of its occurrence is not always 
possible due to our lack of understanding of the pathophysiology. There are two main 
populations considered, asymptomatic and symptomatic, for which there are varying 
methods of PTB prediction. Those who are symptomatic present with threatened preterm 
labour including symptoms such as tightenings, abdominal pain, back pain, pelvic pressure 
and per vaginal bleeding or discharge. The most commonly used methods of PTB prediction 
in UK clinical practice are mid-trimester transvaginal ultrasound CL screening and 
quantitative fetal fibronectin (fFN). Other proposed methods of prediction include biomarkers, 
cervicovaginal fluid (CVF) acetate and the composition of the vaginal microbiome. Though 
several methods have been proposed, no single method alone has been effective in the 
prediction of sPTB. Therefore, the concomitant use of clinical presentation, biomarkers and 
CL screening is currently the most appropriate method of prediction. A newly released 
application, the quantitative instrument for the prediction of PTB (QUiPP) app considers the 
multifactorial nature of sPTB to calculate a percentage risk of sPTB. The ability to accurately 
predict the risk of sPTB during pregnancy not only provides a guide for management, 
avoiding the risk to health and cost-implications of unnecessary treatment, but can also 
serve as reassurance to low-risk women. 
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 TRANSVAGINAL ULTRASOUND 
 
Using transvaginal ultrasound to screen for CL requires the insertion of an ultrasound probe 
into the vaginal anterior fornix and the visualisation of the cervix in the sagittal plane (Figure 
3)38. Serial CL screening using a transvaginal ultrasound scan (TVUSS) in the second 
trimester is a predictor of sPTB in high-risk women39. In symptomatic women over 30+0 
weeks, CL screening is used to predict the likelihood of PTB within 48 hours where a 
CL<15mm indicates the need for treatment and a diagnosis of preterm labour (PTL)40. In 
asymptomatic women, a CL less than 25mm is considered an indication for intervention and 
many studies as well as NICE guidance favour this threshold15, 16, 41. This CL threshold 
corresponds to the 10th percentile at 24 weeks, and has a positive predictive value (PPV) of 
17.8% and negative predictive value (NPV) of 97.4% for prediction of PTB <35 weeks in 
women with a previous PTB42. A 2001 study supported these findings and further 
recommended the use of the 25mm threshold for intervention16. In asymptomatic women 
with prior cervical surgery, mid-trimester CL <25mm has a PPV of 30% and a NPV of 95% in 
predicting sPTB <35 weeks43. 
 




Ultrasound-detectable markers that can indicate the need for intervention are i) funnelling of 
the cervix and ii) the presence of amniotic fluid sludge. These indicators are recommended 
for the screening of high-risk women in specialist PTB prevention clinics in the UK44.  
1.5.1.1 AMNIOTIC FLUID SLUDGE 
Amniotic fluid sludge is hyperechogenic matter or cell debris near the internal os, composed 
of inflammatory cells from the placental microbiome or ascending infection and suggestive of 
an intra-amniotic infection (Figure 4)39. It is an independent risk factor for PTB in 
asymptomatic high-risk women and is associated with an earlier gestational age at delivery, 
lower birthweight, admission to the NICU and an increased risk of neonatal death45. In 
predicting PTB <28 weeks, the combination of CL <25mm and amniotic fluid sludge 
improves prediction over CL screening alone with odds ratios of 14.8 and 6.8 respectively46. 
Therefore, combining the two may allow for the identification of more PTBs47.  
 







Funnelling of the cervix is dilation of the internal os allowing the protrusion of membranes 
into the endocervical canal producing either a U- or V-shape on TVUSS (Figure 5)48. 
Funnelling may be present spontaneously or can be assessed or further pronounced by the 
ultrasound operator applying fundal pressure and observing for a widening funnel-shape at 
the internal os. Care must be taken to avoid wrongly identifying a pseudo-funnel as a true 
funnel, where the lower uterine segment appears to form a funnel above a cervix of 
adequate length49. Studies present conflicting evidence as to whether it is an effective 
predictor of PTB. Some studies state funnelling is associated with an increased risk of sPTB 
in asymptomatic high-risk women48, this is concluded in a 2018 systematic review50. 
Contradictory studies claim there to be no independent association of funnelling to PTB and 
therefore it provides no greater predictive advantage than that of CL screening alone16, 51. 
 
Figure 5: Ultrasound image of cervical funnelling 
 FETAL FIBRONECTIN 
 
Fetal fibronectin is an ECM glycoprotein, released from between the decidua and chorion, 
present within the CVF until 18 weeks’ gestation beyond which it is no longer detectable. 
Width of funnel 




Presence of the glycoprotein in the CVF beyond 18 weeks is indicative of mechanical or 
inflammatory pathology associated with PTB. In symptomatic women over 30+0 weeks, 
where TVUSS is not available, fFN can be used to predict PTB within 48 hours with a 
threshold of 50ng/ml to diagnose PTL and offer treatment40. More recently the use of 
quantitative fFN (the absolute concentration of fFN), which allows for the use of multiple fFN 
thresholds, has been studied for the prediction of PTB within 7-14 days52. This method can 
be used for symptomatic women with cervical dilatation <3mm between 22+0 and 35+6 
weeks and may allow for differing thresholds for offering treatment53. A study of 
asymptomatic high-risk women, including those with previous cervical surgery, demonstrated 
the benefit of multiple fFN thresholds54. Women with fFN <10 ng/mL could be considered low 
risk of PTB <34 weeks based on a high sensitivity and NPV, and a higher risk threshold of 
500 ng/mL may be more appropriate with a positive likelihood ratio (LR) of 1254. In addition, 
the use of fFN alongside serial CL screening has potential to improve the predictive value 
over CL screening alone39, though not all UK specialist clinics opt to use fFN alongside 
routine screening in high risk patients. However, the fFN value can be affected as a result of 
disruption to the cervix through sexual intercourse, digital examination or TVUSS53. In 
practice, fFN is used less frequently in asymptomatic women compared to symptomatic 
women, this may be due to the uncertainty surrounding the most appropriate management of 
this cohort. 
 QUiPP APP 
 
The QUiPP app was designed by King’s College London to calculate the risk of sPTB at 
various gestational ages in both symptomatic and asymptomatic women. The algorithm uses 
transvaginal ultrasound CL, patient history, uterine activity and quantitative fFN to calculate a 
percentage risk of delivery within 1, 2 and 4 weeks and the risk of sPTB <30, <34 and <37 
weeks. The QUiPP app has been used in practice to communicate the risk of sPTB to 
patients and determine when hospitalisation may be necessary for high-risk women. A 
recent study of asymptomatic women at risk of PTB due to a either a previous PPROM, late 
miscarriage or sPTB, concluded that the applying the recommended >10% treatment 
threshold to the QUiPP app would double treatment rates in this cohort, many of which may 
be unnecessary interventions55. However, further studies may be required to determine the 
use of the QUiPP app for planning and appropriately timing preventative interventions in 
women with prior cervical surgery56. In addition to this, further studies would be useful to 
determine an appropriate treatment threshold for this cohort of women.  
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 PHOSPHORYLATED INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-1 
 
Phosphorylated insulin-like growth factor binding protein-1 (PIGFBP-1) is synthesised and 
secreted by the placenta into CVF in response to the onset of uterine contractions. As a 
result, it is a predictor of imminent PTB but its use is limited as a long-term predictor of 
PTB52. Actim partus is a clinical test using monoclonal antibodies to detect PIGFBP-1 in the 
CVF of symptomatic women after 22+0 weeks, however there is currently insufficient 
evidence to recommend its use in practice53. A study of PIGFBP-1 demonstrated an inferior 
PPV of 18.6% relative to 60% for placental alpha-microglobulin-1 (PAMG-1) for predicting 
PTB within 7 days in women with threatened PTL57. PIGFBP-1 also has low predictive 
accuracy for PTB prior to 34 and 37 weeks in asymptomatic women58 and it does not meet 
the criteria for a clinical test to predict sPTB in this cohort59.  
 PLACENTAL ALPHA-MICROGLOBULIN-1 
 
Placental alpha-microglobulin-1 is a glycoprotein produced by the decidua and found in the 
amniotic fluid. The glycoprotein is present in CVF at the onset of labour, likely owed to either 
early contractions or the intra-amniotic inflammation that is more common during labour than 
throughout the earlier stages of pregnancy60. The increase in pressure associated with 
uterine contractions could bring about a leak of amniotic fluid through pre-existing pores in 
fetal membranes. Alternatively, inflammation may lead to the development of small 
perforations in fetal membranes, again allowing for the leak of amniotic fluid, detectable 
within the CVF. The Partosure test, which detects PAMG-1 in vaginal secretions, has 
recently been studied for its use in predicting PTB in symptomatic women with cervical 
dilation <3mm between 20+0 and 36+6 weeks of pregnancy53. PAMG-1 has demonstrated 
statistical significance in predicting preterm delivery within 48 hours, 7 days and 14 days of 
the test as well as the occurrence of sPTB prior to 35 weeks in women with a negative fFN61. 
A study of 383 women with intact membranes and cervical dilation <3cm between 20+0 and 
36+6 weeks demonstrated a PPV of 60% and NPV of 97.7% for predicting sPTB within 7 
days57. The Partosure test also offers the advantages of a quicker result turnaround than 
that of fFN and it is performed without the use of a speculum which increases both ease of 
testing and patient comfort60. However, due to insufficient evidence it is currently not 
recommended for use in UK clinical practice53. 
 CERVICOVAGINAL FLUID ACETATE 
 
Cervicovaginal fluid acetate is produced in large amounts in the vaginal microbiota and may 
be utilised in the prediction of PTB52. Studies reporting the effectiveness of acetate in 
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predicting PTB are limited, though some existing studies have considered its use for women 
symptomatic of PTL. In symptomatic cases, it has been reported that CVF acetate presents 
as good a predictive value as CL screening and fFN for onset of labour prior to 37 weeks or 
within 2 weeks of testing62. A combination of the three further enhances the prediction of 
PTB <37 weeks with a positive likelihood ratio (LR) of 5.0 and negative LR of 0.262. Further 
studies are required to determine whether CVF acetate could be effective as a clinical test, 
though it is unlikely to be of use in a background population of asymptomatic women at high 
risk of PTB due to prior cervical excision. CVF acetate has other limitations including its use 
as a predictor of PTB when used early in pregnancy for those not at immediate risk. 
 VAGINAL MICROBIOME 
 
The future of prediction of SPTB in asymptomatic women may include the use of the vaginal 
microbiome. It has potential as a predictor of PTB, though the practicalities of bacterial DNA 
sequencing are still being developed52. In a normal, healthy pregnancy only a few 
lactobacillus species, of which there are 5 community state types (CST), are expected within 
the vaginal microbiome. It has been observed that women who deliver preterm, have a 
lesser diversity in the vaginal microbiome between 15-20 weeks’ gestation, relative to those 
who proceed to deliver at term. After 20 weeks, little difference can be found between 
women with term and preterm outcomes and therefore the utility of the vaginal microbiome 
as a predictor of PTB decreases beyond this point63. These findings are supported by 
another study that described the predominance of CST IV (diverse species) and an overall 
paucity of lactobacillus, in association with a second trimester short cervix and subsequent 
PTB64. This study collected samples predominantly in African-American women, on average 
4 weeks later than a similar study by Kindinger et al.65 This study found an over-
representation of CST III (L.iners) at 16 weeks’ gestation, in samples largely from Caucasian 
women that went on to deliver before 34 weeks65. This demonstrates the variability of the 
vaginal microbiome by ethnicity, and its further changeability throughout pregnancy. 
1.6 PREVENTING PRETERM BIRTH  
 
As sPTB is multifactorial in nature, there are several proposed mechanisms to prevent its 
occurrence. There is a large evidence base considering interventions in high risk women 
during pregnancy to prevent PTB. However, there is no consensus as to which is the most 
effective intervention66. In addition, these studies of high-risk cohorts are inclusive of women 
with prior sPTB, previous PPROM, previous mid-trimester loss, uterine anomalies, cervical 
surgery, cervical incompetence, short cervix and threatened PTL. Only a few studies include 
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an adequate sample size of cervical excision participants to perform subgroup analysis, 
however no such studies have attempted this. It is also not possible to extrapolate results for 
cervical surgery participants from other high-risk cohorts, as the mechanisms leading to PTB 
in these groups may differ leading to differential treatment effects. UK guidelines currently 
recommend the use of either cervical cerclage, vaginal progesterone (VP) or Arabin pessary 
to prevent PTB in women with prior cervical surgery15. Though there are some studies 
investigating the use of cerclage in this group, there are fewer investigating VP and the 
Arabin pessary. The lack of studies comparing the use of either VP of the Arabin pessary to 
a control group, and the comparison of these interventions to one another and cerclage, 
feeds into the uncertainty surrounding the management and optimisation of outcomes in 
these patients. Currently the evidence-base is unable to determine the most efficacious 
intervention or in which specific circumstances each may be most appropriate67. 
 VAGINAL CERCLAGE  
 
Vaginal cerclage is the most widely used method to prevent PTB in the UK44, this may be 
due to the larger evidence base surrounding the use of cerclage over that of VP and the 
Arabin pessary. Current UK NICE guidance recommends the use of cerclage in women with 
prior LLETZ or cone biopsy and CL <25mm between 16 and 24 weeks of pregnancy15. This 
prophylactic cerclage acts mechanically, preventing the premature effacement of the cervix. 
Alternatively, a rescue cerclage can be sited in cases of threatened preterm labour to 
reverse dilation of the cervix and exposure of fetal membranes. The two main methods are 
Shirodkar and McDonald (Figure 6) with the option to use either monofilament such as nylon 
or a non-absorbable braided polyester suture. The McDonald technique involves the 
placement of a stitch at the cervicovaginal junction whereas a Shirodkar cerclage is placed 
more superiorly at the level of the cardinal ligaments, after reflection of the bladder. Both 
methods require regional anaesthesia as a minimum. The knot can be tied posteriorly to 
avoid bladder irritation or erosion caused by an anterior knot, though a posterior knot can 
present difficulties in removing the suture prior to delivery where the cervix may have 
migrated posteriorly. Insertion of a cerclage increases the risk of bacterial colonisation and in 
turn the risk of puerperal pyrexia. It is thought that monofilament confers a risk of bacterial 
colonisation though some have suggested it may be preferable to a braided cerclage in 
reducing the risk of PTB in patients with a short cervix68. Other risks associated with the 
insertion of a cerclage include causing uterine contractions, bleeding and infection which can 
result in either PTB or miscarriage69. Vaginal bleeding, an increase in vaginal discharge and 
abdominal pain may persist for up to 48 hours following the siting of a cerclage and a 
restriction on heavy lifting and/or sexual activity may be advised, though under normal 
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circumstances the literature does not support these recommendations70. Contraindications 
are inclusive of but not limited to signs of uterine infection, active vaginal bleeding and 
uterine contractions15.  
 
Figure 6: (a) McDonald cerclage technique71                                 (b) Shirodkar cerclage technique71 
The literature surrounding the use of cerclage in the treatment of high-risk singleton 
pregnancies is conflicting. A 2017 Cochrane review supported cerclage in women at high-
risk of PTB, compared with expectant management. However, it stated that although data 
were limited for each clinical group, there was no evidence of effect of cerclage on short 
cervix indications69. Jarde et al.72 determined cerclage did not significantly reduce PTB <34 
weeks or <37 weeks in high-risk women compared to the control group, however subgroup 
analysis demonstrated a decreased risk of PTB <37 weeks in women with a short cervix. 
Both of these reviews considered studies with various individual criteria for the inclusion of 
high-risk participants. The definition of at-risk participants extended beyond prior excisional 
procedures to include; previous PTB, 2nd trimester loss or PPROM, physical examination or 
ultrasound-detected cervical changes, history of cervical cerclage and uterine malformations. 
Jarde et al.72 included only one study of women with prior cervical surgery and therefore 
authors were unable to perform subgroup analysis. Though historically cerclage has been 
considered effective for women with prior cervical excision, other interventions may be more 
advantageous in this cohort.  
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 VAGINAL PROGESTERONE 
 
Progesterone is an inhibitor of the inflammatory process leading to PTB73, a reduction in 
progesterone is responsible for inducing the cervical ripening in the onset of parturition74. 
Increasing local progesterone has been presented as one option to prevent the initiation of 
PTB by inhibiting the inflammatory process associated with PTB. VP causes a decrease in 
the proportion of decidual CD8+CD25+Foxp3+ T cells, neutrophils and macrophages while 
increasing the proportion of CD4+ regulatory T cells, producing an anti-inflammatory 
microenvironment75. It is usually administered in the form of a vaginal pessary, inserted by 
the patient on a daily basis. Progesterone therapy can result in common side effects such 
as; irritation at the site of administration, headache, drowsiness, dizziness and oedema 
although these are usually mild5. A 2013 Cochrane review determined progesterone is 
effective in reducing PTB <34 and <28 weeks in women with a short cervix, though this 
included studies using either intramuscular (IM) or VP76. Similarly, a 2018 meta-analysis 
including 5 randomised controlled trials (RCT) comparing progesterone to placebo or no 
intervention, in singleton pregnancies with a mid-trimester short cervix, found VP significantly 
reduced the risk of PTB along with neonatal morbidity and mortality77. This is supported by a 
further meta-analysis demonstrating the ability of VP to reduce PTB <34, PTB <37 weeks 
and neonatal death78. In addition, the most recent review demonstrated the efficacy of 
progesterone in preventing PTB <34 weeks in asymptomatic high-risk women79. It was noted 
that the absolute risk reduction is most significant for women with a short cervix and 
therefore progesterone may present the greatest benefit in this group79. However, a large-
scale multicentre randomised trial (OPPTIMUM study) demonstrated no benefit of VP in 
reducing the risk of PTB in high risk women due to either previous sPTB, previous 2nd 
trimester loss or a short cervix <25mm80. These findings are supported by the PROGRESS 
trial that also found no reduced risk of PTB or improved neonatal outcomes following the use 
of progesterone in women with a prior sPTB81.  
 ARABIN PESSARY 
 
The siting of an Arabin pessary in high-risk singleton pregnancies is a less invasive and 
often patient-favoured alternative to cerclage82. It is inserted longitudinally with the 
lubrication of antimicrobial cream or gel, unfolded within the vagina and pushed upwards 
towards the vaginal fornix to surround the cervix. Following the initial siting of the pessary, 
the adequacy of its placement is assessed along with CL at follow-up appointments. 
Removal takes place routinely at 37 weeks83. Although the exact mechanism is unknown, 
theories suggest the pessary contributes to a relief of pressure on the internal os due to an 
alteration in the weight distribution of the uterus, or alternatively, it acts as an added barrier 
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to infection84. The success of the Arabin pessary in preventing delivery before 34 weeks may 
also be due to an alteration in the uterocervical angle, which becomes more acute and 
results in a slight cervical elongation, sacralisation of the cervix and a reduction in 
funnelling85. This acts to reduce the contact of fetal membranes with the vagina. The most 
commonly reported side effect is a noticeable increase in white, non-offensive vaginal 
discharge86. Some patients report discomfort87 and others may experience displacement of 
the pessary. A magnetic resonance imaging (MRI) observational study determined the rate 
of displacement of the pessary is notably higher in patients post-KCB than in other groups85. 
Despite these side effects, the Arabin pessary presents a cost-effective and non-invasive 
management option for preventing PTB, without the need for anaesthesia or repeated 
intervention. Two RCTs treating women with a short cervix at 20-24 weeks’ gestation 
determined no greater efficacy of the Arabin pessary over expectant management in the 
prevention of sPTB <34 weeks gestation87, 88. These results were in contrast to another RCT 
vouching for the efficacy of the Arabin pessary in preventing sPTB <34 weeks gestation89. 
There are no studies comparing the efficacy of the Arabin pessary to either control or 
comparator groups specifically in women with a short cervix due to a prior excisional 
procedure. It is therefore difficult to draw conclusions as to the effectiveness of the pessary 
and how its performance compares to that of cerclage and VP in this group. Figure 7 shows 
the Arabin pessary. 
 
Figure 7: Arabin pessary (a) inner diameter (b) outer diameter (c) lateral view89 
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 TRANSABDOMINAL CERCLAGE 
 
A transabdominal cerclage (TAC) is sited typically prior to pregnancy, though they can be 
sited during early pregnancy. They are recommended in cases of large excision, such as 
radical trachelectomy, where a significant portion of cervical stromal tissue has been 
removed, thus greatly impacting on the integrity of the cervix. A TAC can also be used in 
cases of significant anatomical defects or a prior failed transvaginal cerclage. In a similar 
approach to the Shirodkar cerclage technique, TAC involves the placement of the suture at 
the level of the internal os necessitating delivery via caesarean section. The open technique 
requires peritoneal entry and general anaesthesia resulting in a prolonged recovery time and 
increased maternal risk over that of vaginal cerclage techniques5. Alternatively, a TAC can 
be placed laparoscopically with the aim to reduce the risks and recovery time associated 
with open surgery while closely replicating the technique, without routine reflection of the 
bladder90. The suture may be sited in either the anteroposterior or posteroanterior direction, 
with an anterior knot causing potential bladder erosion but a posterior knot increasing the 
risk of adhesions in the pouch of Douglas. Most of the risks associated with the procedure 
are related to the cerclage itself, however the laparoscopic technique does provide additional 
risk of visceral and major blood vessel damage. Some complications associated with TAC, 
regardless of the technique used, include induction of PTB, intrauterine death, premature 
rupture of membranes, suture migration, uterine rupture and intrauterine growth restriction, 
though these are rare91. Although only some specialists currently site TACs laparoscopically, 
it is likely this technique will be the future of transabdominal cerclages. Figure 8 
demonstrates the location of a cerclage resulting from each technique90. 




 COMBINED THERAPIES 
 
Interventions can be combined throughout pregnancy in a further attempt to prevent PTB. 
The use of an Arabin pessary concomitantly with VP has been studied in high risk 
pregnancies, including those with prior cervical surgery. Stricker et al.92 suggested the 
potential  benefit of combining pessary and progesterone, although the study presented no 
benefit in the reduction of PTB rate <34 weeks’ gestation, it did demonstrate a shortening in 
the NICU stay following combined therapy compared to the use of VP alone. Nicolaides et 
al.87 in their 2016 RCT also found no additional benefit in combining VP with an Arabin 
pessary for the prevention of sPTB. However, only women with CL<15mm received the 
combination whereas those in the comparison group had a CL of 15-25mm, this could have 
been a potential source of bias as a shorter CL confers a greater risk of PTB. Despite this, 
these findings were supported by those of another 2016 randomised open-label trial93. 
There are few studies detailing the outcomes resulting from the combination of an Arabin 
pessary and cerclage in women with prior conisation of the cervix. Wolnicki et al.94 
demonstrated no statistically significant benefit to this combination in prevention of sPTB 
<34 weeks’ gestation, however neonatal outcomes including birthweight and shortened 
length of NICU stay were improved, though the small sample size and retrospective design 
may indicate the presence of confounders. These results are similar to those seen in the 
Stricker et al.92 study of the Arabin pessary combined with VP and both studies present a 
case for the combination of interventions for the improvement of neonatal outcomes if not to 
prolong gestation at delivery. 
In cases where progressive shortening is identified following VP administration in 
subsequent TVUSS assessment of CL, it may be necessary to site a cerclage. Or 
conversely in patients with a prior cerclage and further cervical shortening, VP may be 
required as an adjuvant preventative measure. In these patients, it must be determined 
whether VP is of further benefit once a cerclage has been sited or whether the combination 
of the two interventions is futile. Roman et al.95 in a retrospective cohort study found a 
statistically significant increase in gestation of delivery following combined therapy relative to 
cerclage alone. Again, there are a lack of studies considering the use of both VP and 
cerclage prophylactically in women with prior excision of the cervix. Many of the existing 
studies either use different cohorts or inadequate sample sizes to draw conclusions. Larger 
prospective randomised trials are required to determine the potential benefits of this 
combination of interventions in preventing PTB. 
Some publications have studied the use of a combination of all three interventions, cerclage, 
Arabin pessary and VP in order to determine whether increasing the number of interventions 
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confers a decrease in risk of PTB. One study demonstrated a similar efficacy of this 
combination of interventions, relative to groups receiving pessary and VP, cerclage and VP 
or VP alone, in reducing sPTB <37 weeks96. Therefore, the combination of all three 
interventions may increase the incidence of side effects and the cost of treatment in these 
patients, while providing no significant benefit to obstetric outcomes. A Jarde et al.97 
systematic review of studies using a variety of combinations of interventions found no 
determinable benefit nor risk for any combination. The use of multiple concurrent 
interventions to manage sPTB in women with prior excisional procedures is not widely 
studied and therefore it is difficult to draw conclusions from the available evidence. Further 
studies are required to determine the potential benefits of using multiple interventions during 
a single pregnancy. 
 17- ALPHA HYDROXYPROGESTERONE CAPROATE 
 
Weekly IM injections of 17-α hydroxyprogesterone caproate (17-OHPC) have been studied 
as a potential preventative measure in women with a short cervix. The mechanism by which 
17-OHPC impacts PTB is not well understood, but it does not appear to act as VP does to 
inhibit inflammatory processes75. The evidence surrounding the use of 17-OHPC is 
conflicting, though there is evidence for 17-OHPC reducing rates of PTB in women with prior 
sPTB98, this has only recently been replicated in participants at risk due to a short cervix.  A 
2013 review by Romero et al.74 concluded there is no additional benefit in using 17-OHPC to 
prevent PTB in women with a short cervix. This assertion has been supported by a 2015 
RCT99, though the study design included administering 17-OHPC at gestations later than 
recommended. No adverse maternal effects beyond mild injection site reactions, such as 
bruising and swelling, have been consistently reported following 17-OHPC use100. Overall 
the evidence is conflicting surrounding the use of 17-OHPC in women with a short CL and 
therefore it is not currently recommended in the NICE guidance. However, the 2021 EPPPIC 
review demonstrated the efficacy of 17-OHPC in reducing PTB <34 weeks in high risk 
women, and may have a greater impact in those with a short cervix79. These findings may 
present implications for future practice. 
 LIFESTYLE AND NUTRITION 
 
Lifestyle changes can be key aids to reducing the risk of PTB. Maternal smoking is directly 
associated to the incidence of PTB101, therefore stopping or significantly reducing cigarette 
consumption during pregnancy can further reduce the risk. Stress has also been widely 
linked to the occurrence of sPTB102, and consequently recommendations including obtaining 
sick leave from work are occasionally advised. In cases of complications or threatened PTL, 
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historically bed rest was discussed with patients despite lacking evidence of its benefits. 
More recent studies have shown not only a lack of benefit to reduction in maternal activity 
but also the potential for both psychological and physiological adverse effects103. As a result, 
activity restriction is not recommended in clinical practice104. Several publications discuss 
coitus during pregnancy and the potential increased risk of sPTB. Studies have 
hypothesised this risk to; the cervical ripening properties of the natural prostaglandins found 
within sperm, female orgasm and its ability to stimulate uterine contractions, risk of infection 
especially following the siting of a cerclage, or in the case of short cervix, any direct 
mechanical force on the cervix that may contribute to further cervical instability105. 
Recommendations surrounding the restriction of sexual intercourse must be considered by 
clinicians on a case-by-case basis. However, in cases of significant cervical shortening, 
restriction is currently advised until further studies demonstrate safety data to the contrary106. 
In addition to lifestyle modifications, nutritional supplementation can be used to further 
reduce the risk of PTB in high risk women. A recent Cochrane systematic review found an 
11% reduced risk of PTB <37 weeks and a 42% reduced risk of PTB <34 weeks when 
pregnant women received omega-3 long-chain polyunsaturated fatty acid (LCPUFA) 
supplements throughout pregnancy107. As a result, a minimum of 500mg daily omega-3 
LCPUFA supplements are often recommended throughout pregnancy from 12 weeks, 
especially in women at increased risk of PTB. It is also possible to obtain an adequate 
amount of omega-3 LCPUFA from the diet, provided a substantial portion of oily fish is 
consumed per week. 
1.7 CURRENT UK GUIDANCE 
 
The current UK NHS guidance is outlined in the document entitled saving babies lives 
version 267, which describes the referral criteria, follow-up, screening and management of 
women at risk of PTB. It states, all women with a prior single LLETZ with >10mm depth of 
tissue removed, multiple LLETZ procedures or a single KCB are considered at intermediate 
risk of PTB and must be referred to a specialist clinic by 12 weeks’ gestation. Transvaginal 
ultrasound screening of CL must take place a minimum of once between 18-22 weeks’ and 
all women should receive follow-up at 24 weeks to determine whether they can safely be 
discharged back to routine antenatal care. Fetal fibronectin may be used as an adjunct to 
TVUSS for prediction of PTB risk in those specialist clinics that have the expertise to perform 
such tests67. NICE guidance supports the statements within saving babies lives and 
recommends preventative intervention, in the form of cerclage or VP, for women with a CL 
<25mm in mid-trimester TVUSS screening15. Saving Babies’ Lives also states that 
discussions should be held with these patients, highlighting the current evidence for each 
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intervention, including progesterone, Arabin pessary and cerclage, and the potential risks of 
receiving no intervention67.  
1.8 SYSTEMATIC REVIEWS 
 
Systematic reviews involve combining published, peer-reviewed evidence on a particular 
research topic, allowing for a clear and concise summary of the available evidence. Review 
methods including; search criteria, inclusion and exclusion criteria, PICO, risk of bias 
assessment and the techniques to be used in data synthesis and analysis must be pre-
planned and documented in the form of a research protocol. The PRISMA-P statement 
details the required reporting items for a review protocol108. These protocols must then be 
submitted to PROSPERO, an international database for the registering of review protocols. 
The ability to search for registered reviews within PROSPERO prevents the unnecessary 
duplication of reviews and can help promote research collaboration and transparency 
throughout the review process109. The highest standard of systematic review is a Cochrane 
review, involving meticulous planning and highly structured format allowing for publication 
within the Cochrane database of systematic reviews. However, as Cochrane reviews include 
only RCTs, some subjects are not suitable for this type of review. When adequate standards 
for a systematic review are met, the conclusions can be used for decision-making. 
Particularly within healthcare, the findings of a systematic review can influence guidelines 
and directly impact clinical practice.  
If adequate similarity and acceptable heterogeneity is achieved between the studies included 
in a systematic review, a meta-analysis can be performed to determine an overall effect size 
which increases the statistical power relative to a single study alone110. The strength of 
conclusions drawn from a meta-analysis is directly dependent on the quality of the included 
studies, for example a meta-analysis of well-conducted RCTs can produce a high level of 
evidence111, 112. However, the decision to undertake a meta-analysis must be taken with 
caution to avoid presenting misleading conclusions due to either low quality evidence or 
differing study designs113. Further to this, conclusions drawn from a review may be impacted 
by publication bias, where studies with positive findings are more likely to be published114. 
This highlights the importance of performing a GRADE assessment to consider the presence 
of publication bias and its potential impact on the conclusions of the review. Where studies 
are lacking, small in size or of inadequate study design, gaps in the literature can be 
highlighted, guiding future studies to address this115. A systematic review has been 
undertaken within a chapter of this thesis, to ascertain the availability and robustness of the 
evidence surrounding PTB prevention in women with prior conisation of the cervix. 
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1.9 RETROSPECTIVE COHORT STUDIES  
 
Retrospective cohort studies consider a defined group of patients to look back at risk 
exposure, interventions and outcomes in order to draw conclusions. They are advantageous 
in studies of a particular exposure where the cohort may be limited in size, such as prior 
LLETZ or KCB of the cervix. However, due to the retrospective nature of data collection from 
medical records, several healthcare professionals may have been involved in the care of 
study participants. This may introduce some elements of inconsistency, for example in the 
recording of relevant risk factors or ultrasound screening of CL which is highly operator-
dependent. Although an observational study design does not provide the same strength of 
evidence as an RCT, due to potential bias from covariates and confounding factors, they are 
often utilised in the study of PTB interventions. A recent randomised feasibility study 
determined inadequate power to perform a two-centre RCT on a cohort of women with a 
mid-trimester short cervix due to the small number of eligible participants116. Women with 
successful outcomes in prior pregnancies due to a particular intervention may wish to 
receive the same intervention in subsequent pregnancies and this would present difficulties 
in randomising patients to an intervention. Therefore, a retrospective cohort study design 
was undertaken within this thesis. The study aimed to address the lacking evidence 
surrounding the prevention of PTB in women with prior conisation of the cervix, particularly 
surrounding the use of VP and the Arabin pessary. 
1.10 SUMMARY 
 
Excisional procedures of the cervix represent a significant burden of sPTB annually. 
Optimising the management of these patients has the potential to significantly reduce 
consequent neonatal morbidity and mortality. The current literature surrounding excisional 
procedures of the cervix is growing but remains limited and it is unknown whether VP, 
cerclage or the Arabin pessary is most efficacious in preventing PTB in these women. The 
evidence used in clinical guidance and decision-making is based on either studies of women 
with a prior sPTB, short CL or high-risk cohorts with combinations of risk factors rather than 
women at increased risk of PTB due to prior cervical surgery. Further studies in this area are 
required to determine the optimal follow-up and management of these patients.  
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1.11 HYPOTHESIS AND AIMS 
 
  HYPOTHESIS 
 
This thesis investigated the interventions used to prevent PTB by testing the following 
hypothesis: 
(i) Excisional procedures of the cervix present an increased risk of PTB 
(ii) Vaginal cerclage, VP and the Arabin pessary are all effective prophylactic 
interventions in the prevention of PTB in women with prior KCB or LLETZ of the 
cervix 
(iii) VP or the Arabin pessary may demonstrate greater efficacy over cerclage in 
preventing PTB in this cohort of women 
  AIMS 
 
The aims of this thesis were as follows:  
(i) To conduct a systematic review to determine the current recommended 
intervention(s) to prevent PTB in women with prior excisional procedures of the 
cervix 
(ii) To complete a retrospective cohort study, using single-centre clinic data, to 
establish the risk of PTB in women who have undergone prior KCB or LLETZ 
procedures  
(iii) To synthesize the clinic data in order to determine which intervention presents 








CHAPTER 2 – EFFICACY OF CERCLAGE, PROGESTERONE AND PESSARY IN 
PREVENTING PRETERM BIRTH IN WOMEN WITH PRIOR EXCISION OF THE 
CERVIX: A SYSTEMATIC REVIEW 
2.1      BACKGROUND 
 
Existing studies have demonstrated an increased risk of PTB in women with prior KCB or 
LLETZ procedures to the cervix. The majority of neonatal morbidity and mortality worldwide 
is a direct result of PTB8. KCB and LLETZ procedures are performed following the 
identification of cervical intraepithelial neoplasia grades 2 or 3 in women undergoing routine 
cervical screening. KCB is thought to confer a greater risk of PTB than LLETZ procedures19, 
though some women may undergo several LLETZ procedures which further increases their 
risk due to the removal of a greater volume of cervical tissue31. The PTB risk applies to not 
only the first post-excision pregnancy but to all subsequent pregnancies32 and therefore 
intervention to prevent PTB may be necessary in all future pregnancies for this cohort of 
women.  
UK guidance, from the Saving Babies’ Lives care bundle version 2, considers women with 
either a previous LLETZ >10mm in depth, multiple LLETZ procedures or a KCB as an 
intermediate risk of PTB67. It is advised that pregnant women meeting the above criteria 
should be referred to specialist PTB prevention clinics from 12 weeks’ gestation and should 
receive transvaginal ultrasound screening of CL between 18-22 weeks’ gestation67. Those 
women that are identified to have a CL <25mm on mid-trimester ultrasound screening are 
considered high risk and are offered intervention in the form of either VP, cerclage or Arabin 
pessary in an attempt to prevent the occurrence of PTB15. Some specialist PTB prevention 
clinics also use fetal fibronectin testing alongside CL screening to aid their risk assessment 
of these women. 
A 2018 systematic review screened the guidelines of 16 developers globally, of which 8 
endorsed the use of VP to prevent PTB in asymptomatic women with a CL <20mm on 
TVUSS prior to 24 weeks’ gestation117. Table 1 details the referral, screening and 





Table 1: Guidelines for prevention of PTB in high-risk pregnancies 
Location Criteria for 
screening/referral  
Screening and 






UK15, 67 LLETZ >10mm depth 
2 or more LLETZ 
Single KCB 
18-22 weeks, 
Fetal fibronectin (where 
available) 




Women given an 
intervention should 
remain under 
specialist clinic care 
until delivery and 
should undergo 




LLETZ >10mm depth 
2 or more LLETZ 
Single KCB 









weekly TVUSS until 
23+6 weeks. 
CL <15mm Cervical cerclage 






LLETZ >10mm depth 
2 or more LLETZ 
Single KCB 
14-24 weeks  CL <25mm Cervical cerclage No indication for 
cerclage if prior 
KCB/LLETZ with a 
normal CL 
Belgium120  None related to cervical 
surgery 
14-24 weeks Asymptomatic and 
CL <25mm 
Vaginal progesterone 
200mg once  
“No beneficial or 
harmful effect of 
cerclage has been 
demonstrated in 
women with prior 
cervical surgery” 
Prior sPTB <32 
weeks/recurrent 
2nd trimester birth 
and CL <25mm  
Consider cervical 
cerclage 






Vaginal progesterone  History-indicated 
cerclage is not 
recommended for 
women with a 
history of cervical 
surgery. Routine CL 
screening is not 
recommended. 
Canada122  None related to cervical 
surgery 
16-24 weeks CL <25mm Vaginal progesterone 
200mg daily – this 
should also be 









women already on 








A Cochrane review demonstrated the benefit of cerclage in managing high-risk singleton 
pregnancies, though authors were unable to draw conclusions for women with previous 
cervical surgery, and further stated that the question of whether cerclage is superior to other 
interventions remains unanswered69. Grabovac et al.123 did not support the use of cerclage in 
preventing PTB for women with prior conisation of the cervix. Romero et al.77 published a 
review supporting the use of VP to reduce the risk of PTB in women with a short mid-
trimester CL. This is supported by the findings of the 2021 EPPPIC study published in the 
Lancet79. The evidence surrounding the use of the Arabin pessary is conflicting with one 
study supporting89 and another disputing87 its ability to prolong pregnancy in women with a 
CL <25mm. This can be seen to impact the high-risk pregnancy management guidelines 
globally, with only one of the locations, mentioned above, recommending the use of the 
Arabin pessary. Each of the aforementioned reviews considered the use of interventions to 
prevent PTB in different high-risk cohorts including women with a short cervix, previous PTB, 
and prior cervical surgery. In some cases, this has led to conflicting evidence. This highlights 
the need to consider these varying risk cohorts separately as we cannot assume all high-risk 
groups undergo the same mechanisms leading to PTB or demonstrate an equal response to 
interventions. However, despite the poor obstetric and subsequent neonatal outcomes 
associated with prior cervical surgery, there are a lack of reviews considering the prevention 
of PTB in a cohort of women with prior excisional procedures of the cervix in singleton 
pregnancies alone, specifically those receiving either pessary or progesterone. The results 
of large reviews with other risk groups, such as that of Alfirevic et al.69 and Goya et al.89, 
cannot be extrapolated to this cohort. There is also a lack of consideration for the differential 
risk groups within this cohort i.e. those receiving ultrasound-indicated treatment who are 
likely higher risk for PTB than those who do not develop a short cervix. This review aims to 
address this gap in the evidence-base.  
2.2      AIMS 
 
The aim of this chapter is to identify studies that have analysed obstetric outcomes in 
singleton pregnant women with prior cervical surgery receiving either a cerclage, pessary or 
progesterone to prevent PTB. A secondary aim is to compare the efficacy of these 
interventions in this cohort of women. 
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2.3      METHODS 
 
The systematic review protocol was registered on PROSPERO (CRD42021252327) 
accessed at https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=252327. 
2.3.1 SEARCH STRATEGY 
 
Searches were conducted in February 2021 within Pubmed, Scopus and Medline databases. 
All search terms; “cervical surgery”, “cervical excision”, “LLETZ”, “LEEP”, “cone biopsy”, 
“conisation”, “conization”, “short cervix” and “high risk” were combined using the Boolean 
operator OR. A separate search was conducted using the same Boolean operator to 
combine the terms “cerclage”, “pessary”, “progesterone” and “17-OHPC”. The Boolean 
operator AND was then applied to combine the two separate searches. All articles were 
screened for the presence of these search terms within the title or abstract. Several 
synonyms have been used in publications to describe surgical procedures to the cervix. To 
ensure all possible terms were included, this was discussed with experts within research in 
obstetrics and gynaecology and pilot searches were carried out. The phrases “high risk” and 
“short cervix” were included to account for any studies that did not detail cervical surgery 
within the title or abstract but may have performed subgroup analysis for outcomes of 
interventions in this cohort. Restrictions for English language, human subjects and study 
type were applied. Restrictions were not made based on date of publication and therefore 
results include any relevant study published within or prior to February 2021. 
2.3.2 ELIGIBILITY CRITERIA 
 
Papers were screened for inclusion of participants with singleton pregnancies that had 
undergone prior KCB or LLETZ procedures and were treated with either vaginal cerclage 
(Shirodkar or McDonald), Arabin pessary, progesterone (vaginal, IM or oral) or a 
combination of these interventions during pregnancy. These interventions were compared to 
either a placebo, no intervention or another intervention. RCTs and observational studies 
(cohort and case-control) were included. Any reviews, editorials, books, letters and 
conference papers were excluded. We did not restrict searches based on date of publication. 
Although pessary and progesterone are more recent therapies, there has been little change 
in the management of high-risk patients using vaginal cerclage. Studies looking at outcomes 
in multiple pregnancies, women symptomatic of preterm labour and interventions of 
transabdominal cerclage or double (reinforcing) vaginal cerclage were excluded. Exclusions 
were also made for studies that did not report outcomes on gestational age at delivery or 
incidence of PTB.  
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2.3.3 STUDY SELECTION 
 
Two independent reviewers (FP and AC) screened papers initially by title and abstract 
against pre-determined eligibility criterion. Full studies were then screened for eligibility of 
inclusion. Cases of uncertainty were discussed and disagreements between the two 
reviewers (FP and AC) were resolved by discussion and consensus with a third reviewer 
(AS).  
2.3.4 DATA EXTRACTION 
 
The following information was extracted from eligible studies by a single reviewer (FP), any 
cases of uncertainty were discussed with a second reviewer (AC). Authors were contacted 
for clarification of the cohort risk, indication for intervention and outcomes, where reviewers 
were unable to extract adequate detail from the study. 
(i) Study design and data collection method 
(ii) Population size and presence of PTB risk factors  
(iii) Intervention type and comparator group 
(iv) Obstetric outcomes 
(v) Neonatal outcomes 
The primary outcomes were PTB prior to 34 and 37 weeks. Secondary outcome measures 
included; PTB <32, <28 and <24 weeks, PPROM, onset and mode of delivery, 
livebirth/stillbirth, neonatal death, NICU admission, ventilatory support, use of surfactant, 
respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular haemorrhage, 
periventricular leukomalacia, sepsis, maternal mortality/harm and any side effects or adverse 
events as a result of the interventions124. 
2.3.5 RISK OF BIAS ASSESSMENT 
 
Risk of bias and methodological quality of included studies was assessed by two separate 
reviewers (FP and AC) using a modified version of the Newcastle Ottawa quality 
assessment scale for cohort studies125, as has been recommended previously by the 
Cochrane collaboration126. Under the comparability heading, participants with prior sPTB and 
those that developed a mid-trimester short cervix <25mm were considered to be at the 
greatest risk of confounding. Papers were assessed on their ability to alter inclusion criteria, 
exclude participants or adjust analysis of results to account for these factors. Two sections of 
the assessment were removed including demonstration that the outcome of interest was not 
present at the start of the study and demonstration that follow-up time was adequate. The 
outcomes of interest will not have been present at the time of intervention, as these were 
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carried out during pregnancy and follow-up cannot have occurred sooner than delivery, for 
which patients will likely have attended hospital. Therefore, the maximum score that could 
have been awarded using the modified Newcastle Ottawa tool was 7, indicating a low risk of 
bias. 
2.3.6 GRADING OF EVIDENCE 
 
Evidence was graded as either very low, low, moderate or high quality following the 
approach set out by the GRADE working group127. Grading of evidence was carried out by 
two independent reviewers (FP and AC). Each study was initially given a low grading due to 
the retrospective cohort study design, with the opportunity for upgrading following 
assessment based on risk of bias, inconsistency, indirectness of evidence and imprecision. 
As there were few studies included, formal assessment for the presence of publication bias 
was not carried out. An overall grade was determined for each of the following outcomes; 
PTB <34 weeks, PTB <37 weeks and neonatal mortality. 
2.3.7 STATISTICAL ANALYSIS AND DATA SYNTHESIS 
 
A narrative summary of the results of included studies, structured around the type of 
intervention, characteristics of the target population, the type of outcome and the content of 
the intervention was provided. I2 was used to assess heterogeneity between studies where a 
result of <40% was considered acceptable. The odds ratios, 95% confidence intervals and 
relative risk were calculated for each of the main reported outcomes per study, using the 
Cochrane collaboration software Revman 5.4.1128. Data were presented as forest plots. 
Studies that reported outcomes for history-indicated cerclage and ultrasound-indicated 
cerclage were presented separately to account for the differing PTB risk in these two groups. 
2.3.8 SUBGROUP ANALYSIS 
 
Analysis of differential effects based on (i) previous LLETZ procedure and (ii) previous KCB 
and based on (iii) Ultrasound-indicated cerclage and (iv) history-indicated cerclage was 
planned.  
2.4      RESULTS 
 
2.4.1 STUDY SELECTION 
 
Searches retrieved a total of 1793 results from 3 databases; Pubmed (n = 262), Scopus (n = 
1283) and Cinahl (n = 248). Following removal of duplicates, 1582 articles remained for 
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screening by title and abstract. After exclusion based on title and abstract, 122 articles were 
screened by full-text leaving 6 articles for inclusion in the review. The reasons for exclusion 
of the 116 studies at full-text screening were; a lack of participants with cervical surgery (n = 
61), a lack of subgroup analysis for cervical surgery participants (n = 50), a lack of 
comparator group (n = 1), transabdominal cerclage (n = 2), full-text not in English (n = 1) and 
case report (n = 1). Figure 9 is a PRISMA flowchart129 summarising the study screening 
process.  
  




2.4.2 QUALITY OF INCLUDED STUDIES 
 
All included studies were retrospective cohort studies and therefore risk of bias was 
assessed for each study using a modified version of the Newcastle Ottawa bias assessment 
tool for cohort studies. As per the modified tool, a score of 0-2 indicated a high risk, 3-5 a 
moderate risk and 6-7 a low risk of bias, with 7 being the highest achievable score. Two 
studies achieved a score of 7 having demonstrated an appropriate study methodology 
including adequate adjustments for the two major confounding factors. Three studies 
achieved the lowest recorded score of 5, having made no adjustments for the presence of 
confounders. A summary of the risk of bias assessment for each paper is presented in Table 
2. 
Table 2: Newcastle-Ottawa risk of bias assessment summary125  













   7 Low 




 -   5 Moderate 
Shin (2010)    7 Low 
Nam (2010)  -   5 Moderate 
Zeisler (1997)     6 Low 
 
2.4.3 GRADE ASSESSMENT  
 
Table 3 summarises the GRADE assessment of the quality of evidence for each of the main 
reported outcome measures. The quality of evidence can vary between outcomes and 
therefore it is necessary to assess these individually. I2 was used to assess inconsistency, 
this was high for each outcome indicating a strong likelihood of considerable heterogeneity 
within the studies. The quality of the included evidence on each outcome was considered 
very low. Due to the low quality of the included studies, the significant presence of 
heterogeneity and the slightly differing cohorts and criteria for intervention in each study, it 







Table 3: GRADE assessment of key outcomes 
 
 
Table 4 summarises the reasoning for the ratings awarded under each domain per outcome. 
Table 4: Reasons for downgrading/upgrading evidence as per GRADE 
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N/A -1 No change Very low Important 
Outcome Reason for grade awarded to each domain 
Risk of bias Inconsistency Indirectness Imprecision 
PTB < 34 weeks All 3 studies were 
retrospective cohort, 
1 did not adequately 
adjust for 
confounders.  





indicated and 1 a 
mix of both. 




that of 2 studies 
crossed line of 
no effect. 
PTB <37 weeks All 5 studies were 
retrospective cohort, 
4 did not adequately 
adjust for 
confounders. 
I2 >90% Mixture of 
indications for 
cerclage. 




that of 3 studies 
crossed the line 








adjusted for 2 major 
confounders. 
Incalculable Did not present 
data from 
subgroup analysis 











2.4.4 STUDY CHARACTERISTICS  
 
All six of the included studies were retrospective cohort studies. Of the six included studies, 
one was from the UK, one from Austria, one from Israel and three from South Korea. All six 
examined the obstetric outcomes following insertion of a cerclage. Two studies included 
participants with a prior KCB, one study included participants with a prior LLETZ procedure, 
two studies included participants with either LLETZ or KCB and one study did not specify 
further beyond “conisation”. Despite contacting the corresponding author, we received no 
response and therefore did not establish the type of cervical surgery participants had 
undergone. The main technique used for cerclage was the McDonald technique, though 
three studies did not specify the exact technique used and one study included 3 participants 
that had Shirodkar cerclages. Only history-indicated cerclages were sited in one study and 
ultrasound-indicated cerclages alone were sited in one other study. Two studies had a 
mixture of indications for siting a cerclage, one of which performed subgroup analysis for 
those participants receiving an ultrasound-indicated cerclage. The remaining two papers did 
not explicitly specify the indication for cerclage for each participant. The characteristics of the 
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56 CL <25mm  
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2.4.5 RESULTS OF INCLUDED STUDIES  
 
Of the included studies, three reported outcomes for the incidence of PTB <34 weeks, five 
reported outcomes for PTB <37 weeks and four reported outcomes for PPROM. Only two of 
the studies reported on neonatal outcomes. Shin et al.132 was the only study to report 
outcomes on neonatal morbidity and mortality, for many of which we were unable to 
calculate an odds ratio (OR), relative risk (RR) or corresponding 95% confidence intervals 
(95% CI) due to a lack of events. Of the 1075 participants within the Cho et al.130 study, 28 
were multiple pregnancies for which authors did not perform subgroup analysis to account 
for the differential outcomes that may be seen in this group relative to singleton pregnancies. 
Table 6 contains a summary of the results of the included studies. 
Table 6: Summary of results of included studies 
 
 
Outcome Study No. of participants OR (95% CI) RR 
Cerclage No cerclage 
PTB <34 weeks Kindinger (2016) 6/98 8/627 5.05 (1.71-14.87) 4.80 
Rafaeli-Yehudai 
(2014) 
7/22 5/87 7.65 (2.14-27.33) 5.54 
Shin (2010) 5/25 6/31 1.04 (0.28-3.92) 1.03 
PTB <37 weeks Kindinger (2016) 24/98 46/627 4.10 (2.36-7.10) 3.34 
Cho (2018) 17/161 39/914 2.65 (1.46-4.81) 2.47 
Shin (2010) 9/25 9/31 1.38 (0.45-4.24) 1.24 
Nam (2010) 3/6 15/59 2.93 (0.53-16.12) 1.97 
Zeisler (1997) 7/30 8/39 1.18 (0.37-3.72) 1.14 
PTB <28 weeks Shin (2010) 2/25 2/31 1.26 (0.16-9.65) 1.24 
PPROM Cho (2018) 10/161 22/914 2.69 (1.25-5.78) 2.58 
Rafaeli-Yehudai 
(2014) 
3/22 17/87 0.65 (0.17-2.45) 0.70 
Shin (2010) 10/25 13/31 0.92 (0.32-2.70) 0.95 
Zeisler (1997) 4/30 6/39 0.85 (0.22-3.32) 0.87 
Neonatal 
mortality 
Shin (2010) 0/25 0/31 - - 
NICU admission Kindinger (2016) 10/98 8/627 8.79 (3.38-22.88) 8.00 
Shin (2010) 4/25 7/31 0.65 (0.17-2.55) 0.71 
Neonatal morbidity 
RDS Shin (2010) 3/25 0/31 - - 
BPD Shin (2010) 2/25 0/31 - - 
PVL Shin (2010) 1/25 0/31 - - 
IVH Shin (2010) 0/25 0/31 - - 
ROP Shin (2010) 0/25 0/31 - - 
NEC Shin (2010) 0/25 1/31 - - 
Sepsis Shin (2010) 1/25 3/31 0.39 (0.04-3.99) 0.41 
Ventilation Shin (2010) 3/25 1/31 4.09 (0.4-42.01) 3.72 
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2.4.5.1 PTB <34 WEEKS 
 
All three studies reporting on PTB <34 weeks demonstrate greater odds of the outcome 
occurring following the siting of a cerclage relative to participants that received no 
intervention. Two of these studies had wide confidence intervals and the remaining study 
had a confidence interval crossing the line of no effect, demonstrating a lack of certainty over 
these outcomes (Figure 10).  
 
Figure 10: Forest plot without meta-analysis for studies reporting on PTB <34 weeks128 
 
2.4.5.2 PTB <37 WEEKS 
 
Five studies reported greater odds of PTB <37 weeks for participants receiving a cerclage 
relative to those that received no intervention. Again, three of the studies had confidence 
intervals crossing the line of no effect (Figure 11). 
 











2.4.5.3 SECONDARY OUTCOMES 
 
Cho et al.130 demonstrated PPROM is more likely following intervention with cerclage (OR 
2.69, 95% CI 1.25-5.78), however this was not supported by the 3 other studies reporting on 
this outcome, each demonstrating a decreased risk, though the confidence intervals crossed 
the line of no effect (Figure 12). 
 
Figure 12: Forest plot without meta-analysis for studies reporting on PPROM128  
Kindinger et al.68 found increased odds of NICU admission following the siting of a cerclage 
(OR 8.79, 95% CI 3.38-22.88), however this finding is not supported by that of the Shin et 
al.132 study (OR 0.65, 95% CI 0.17-2.55). Further to this, Shin et al.132 reported extensively 
on adverse neonatal outcomes, of which there were few events including no neonatal 
mortality in either the intervention or comparator groups. Based on only four events between 
the two groups for each of sepsis and requirement for ventilation outcomes, it is difficult to 
draw useful conclusions from these results. Of the 6 included studies, none reported 
maternal adverse events, side effects as a result of the intervention or onset of delivery. 
Though 3 studies reported mode of delivery, we were unable to ascertain the cause of these 
modes and therefore this outcome lacks practical use without onset of delivery data. 
2.4.5.4 ULTRASOUND-INDICATED CERCLAGE  
 
Two studies reported outcomes on ultrasound-indicated cerclages, sited for a CL <25mm. A 
total of 98 out of 725 participants received a cerclage in the study by Kindinger et al.68 as a 
result of a mid-trimester CL <25mm. This indicates that 13.5% of women with prior cervical 
surgery will develop a short cervix and require an intervention to prolong pregnancy. All 
women with a short CL received a cerclage and as a result we could not calculate odds 
ratios and confidence intervals for the Kindinger study. Shin et al.132 performed subgroup 
analysis for 19 patients within the study cohort that had a short CL <25mm, two further 
participants developed funnelling and received a cerclage but these were not included in the 
subgroup analysis. Shin et al.132 demonstrated a decreased likelihood of PTB <37 weeks in 
women with a cerclage relative to women that were not treated (RR 0.58, OR 0.44, 95% CI 
0.06-3.24), though these results are based on only 6 events (Table 7). 
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Table 7: Primary outcomes for ultrasound-indicated cerclage 
 
2.4.5.5 HISTORY-INDICATED CERCLAGE 
 
All participants received a history-indicated cerclage in the Rafaeli-Yehudai et al.131 and 
Zeisler et al.134 studies contrast to only 11 of the participants within the Shin et al.132 study. 
The studies indicate an increased risk of delivering prior to 37 weeks, following the siting of a 
history-indicated cerclage for prior cervical surgery. We were unable to calculate an odds 
ratio, 95% confidence interval or relative risk for the subgroup within the Shin et al.132 study 
as the details for these participants were not recorded separately within the study. The 
confidence intervals are wide in the results of the Rafaeli-Yehudai et al.131 study and cross 
the line of no effect in the Zeisler et al.134 study (Table 8). 









OR (95% CI) RR 
PTB <34 
weeks 
Kindinger (2016) 6/98 0.06 - - 
PTB <37 
weeks 
Kindinger (2016) 24/98 0.24 - - 
Shin (2010) Cerclage: 3/12 
No cerclage: 3/7 
0.32 0.44 (0.06-3.24) 0.58 











No cerclage: 5/87 
0.32 5.05 (1.71-14.87) 4.80 
PTB <37 
weeks 
Shin (2010) Cerclage: 6/11 0.54 - - 
Zeisler (1997) Cerclage: 7/30 
No cerclage: 8/39 
0.23 1.18 (0.37-3.72) 1.14 
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2.5      DISCUSSION 
 
This systematic review aimed to identify any studies of cerclage, pessary or progesterone to 
determine which intervention has the greatest efficacy in preventing PTB in women with 
singleton pregnancies and prior cervical surgery. The only published studies in this cohort 
focussed on cerclage and therefore we could not determine the comparative efficacy of 
progesterone and Arabin pessary in preventing PTB due to the paucity of evidence. In 
addition, the available evidence surrounding the use of cerclage in this cohort is of 
insufficient quality to draw conclusions. All studies reporting on the primary outcomes (n = 6) 
demonstrated an increased risk of PTB prior to both 34 and 37 weeks following the siting of 
a cerclage in asymptomatic women with a history of cervical surgery. However, this effect 
may be due to the identification of a high-risk subgroup of women that developed a short 
cervix and received an intervention relative to those that did not. These results must also be 
interpreted with caution due to the significant level of heterogeneity between studies and the 
very low-quality evidence as assessed using GRADE. In addition, 4/8 of the primary 
outcome confidence intervals crossed the line of no effect, indicating an uncertainty in the 
direction of these outcomes. 
As aforementioned, women with previous cervical surgery that develop a mid-trimester CL 
<25mm, and subsequently receive a preventative intervention, are at a higher risk of PTB 
than those that do not experience cervical shortening and receive no intervention. Short mid-
trimester CL may be the greatest indicator of PTB risk in women post-conisation133 and 
therefore regardless of intervention, this cohort may still deliver at an earlier gestation than 
participants that do not develop a short cervix. Therefore, we cannot conclude that the 
occurrence of PTB is a direct result of the vaginal cerclage. Notwithstanding, the included 
studies are the best available evidence to determine the efficacy of cerclage in preventing 
PTB in women with prior LLETZ or KCB of the cervix. In any study of women with a short 
cervix, it would be unethical to offer the option of placebo or no intervention and therefore 
the best method of determining the efficacy of an intervention in future studies would be 
through direct comparison to another intervention. 
The included studies varied in their indications for siting cerclages, with studies siting only 
history-indicated cerclages (n = 2), only ultrasound-indicated cerclages (n = 1), or a mixture 
(n = 2). As the risk of PTB between these groups differs, it is not possible to draw 
comparisons between these studies and this limited the generalisability of the findings from 
this review. However, our subgroup analysis for history-indicated cerclage may be useful to 
determine both the risk of delivering preterm and the efficacy of cerclage in women at 
intermediate risk. The overall rate of PTB <37 weeks in the untreated arm of the Zeisler et 
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al.134 study is 20.5% which is greater than the background population rate of approximately 
7.3% in the UK135, demonstrating the increased risk in women with previous cervical surgery 
relative to the background population. Both the Zeisler et al.134 and Rafaeli-Yehudai et al.131 
studies sited prophylactic cerclages. These studies provide a fairer comparison between the 
performance of cerclage versus no cerclage groups as the outcomes are not influenced by 
short CL and therefore participants are at a similar risk of PTB. Again, the findings indicate 
an increased risk of PTB in this cohort when managed with cerclage relative to no cerclage. 
It is more likely these results are linked to the cerclage, although bias due to confounding 
cannot be discounted due to the retrospective study designs. This increased PTB risk may 
be due to the bacterial colonisation and ascending infection associated with the siting of a 
cerclage76. Women with a prior KCB and no further indication should not be offered an 
intervention to prevent PTB, as is stated within several medical guidelines globally.  
The results of cerclage studies may also be impacted by the suture material used. Kindinger 
et al.68 aimed to determine the optimal suture material between braided and monofilament 
cerclage materials. Authors concluded that monofilament was the superior suture material 
and therefore this may have some influence on the performance of cerclage in studies 
considering the efficacy of vaginal cerclage. Currently, a large randomised clinical trial of 
cerclage materials (C-STICH), is due to publish findings and these may guide both future 
research and clinical practice in this area136. The Kindinger et al.68 study also presents 
practical use as its methods closely replicated UK clinical practice and this gives an 
indication of the proportion of women (13.5%) with previous cervical surgery that would 
develop a short cervix and require an intervention to prolong pregnancy.  
A recent study demonstrated parents highly value neonatal outcomes to assist in making 
healthcare decisions during pregnancy with 72% of parents valuing outcomes for offspring 
mortality and 68% favouring outcomes for neurodevelopmental morbidity and infection124. 
Only one of the included studies, Shin et al.132 publishing a complete core set of neonatal 
outcomes, yet the study cohort was relatively small leading to a limited number of events for 
each outcome. As a result, it is not possible to draw conclusions on the impact of cerclage 
on neonatal outcomes. Although the majority of adverse neonatal outcomes may be owed to 
PTB, it is difficult to ascertain and predict any adverse long-term effects following an 
intervention to prevent PTB without these outcomes. This may also present further problems 
in counselling patients who value this information for decision-making. 
There is only one published review comparing interventions in a cohort of women with 
previous cervical surgery. This review by Grabovac et al.123 corroborated the findings of our 
review and authors did not support the use of cerclage for prevention of PTB. However, the 
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results face the same limitations as ours and may also be biased due to confounding factors, 
as reported by the review authors123. The review also included a random-effects meta-
analysis of studies but reviewers did not perform subgroup analysis to account for the high-
risk subgroup of women with a short cervix relative those without and therefore results may 
be misleading. Contrast to the results of this review, and based on a broad high-risk cohort, 
Alfirevic et al.69 concluded cerclage is an effective intervention in prolonging pregnancy, 
though there was insufficient evidence for the subgroup of women with a short cervix alone. 
However, subgroup analysis for women with a short cervix in a review by Jarde et al.72 
demonstrated cerclage was effective in reducing PTB <37 weeks though results were not 
significant for prevention of PTB <34 weeks. Unfortunately, these results cannot be 
extrapolated to women with previous cervical surgery due to the uncertainty surrounding the 
mechanisms leading to PTB in various high-risk groups. This highlights the ongoing sparsity 
of evidence surrounding the management of this cohort of women and the further 
implications this has for clinical practice. 
There are no published studies on the use of Arabin pessary or progesterone to prevent PTB 
in women with previous cervical surgery. As a result, we were unable to draw any 
conclusions for these interventions or determine how their efficacy compares to cerclage in 
this cohort. The evidence for the use of VP remains conflicting although the most recent 
review, EPPPIC79, in congruence with a previous review by Romero et al.77, demonstrated 
its efficacy in women with a short cervix. This is in contrast to the findings of the OPPTIMUM 
study80 which did not support the use of progesterone in the same cohort. Again, studies of 
the Arabin pessary present contradictory evidence for women with a short cervix. Goya et 
al.89 conducted the only study to support the use of the Arabin pessary in this cohort. Both 
Nicolaides et al.87 and Hui et al.88 found no additional benefit of the pessary over expectant 
management in women with a CL <25mm. There is an urgent need for further studies of 
these interventions to guide future practice for women with previous cervical surgery. A 
multi-centre randomised feasibility study should be conducted to determine whether this is a 
possibility and guide further studies. 
2.5.1 IMPLICATIONS OF THE REVIEW 
 
This systematic review did not identify any studies exclusively examining the effects of VP or 
Arabin pessary in this population. A Cochrane review of systematic reviews was unable to 
draw conclusions on the use of these interventions in high-risk women due to the paucity of 
evidence137. Future prospective studies, most favourably in the form of a multi-centre RCT, 
should be undertaken to determine the efficacy of these interventions and guide clinical 
practice for women with previous cervical surgery and a mid-trimester short cervix. This 
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review also demonstrated clear benefit from the use of cerclage in singleton pregnancies at 
high risk of PTB137. However, we are unsure as of yet, whether managing these women 
among a generic high-risk cohort would be appropriate or whether guidelines must be 
adjusted to account for the differing risk in women with prior cervical surgery. Further to this, 
it will be useful to ascertain whether the type of cervical surgery has any impact on the 
efficacy of the interventions in preventing PTB. Studies already suggest that a KCB more 
significantly increases the risk of PTB than LLETZ procedures due to the greater depth of 
tissue excised19, 22. Therefore, studies including subgroup analysis for KCB, single LLETZ 
and multiple LLETZ procedures within studies would be valuable in gaining insight into the 
impact on the efficacy of interventions.   
Systematic reviews by Alfirevic et al.69 (2017) and Grabovac et al.123 (2019), both highlighted 
the need for more studies in this area. Yet there has been little advance in our knowledge of 
managing women with prior conisation of the cervix. There remains a need for further 
retrospective cohort studies and, where feasible, prospective studies to determine the 
efficacy of these interventions. A recent randomised-feasibility study described the 
challenges in performing an RCT of women with a short cervix in a single centre due to the 
low participant numbers in this group116. Therefore, the cohort of women with prior cervical 
surgery that develop a mid-trimester short cervix and require an intervention would be even 
smaller and likely present further challenges. Further to this, where patients have previously 
had positive pregnancy outcomes when treated with a particular intervention, they may wish 
to receive the same intervention in subsequent pregnancies and this may present difficulties 
in randomising participants to an intervention. Therefore, the best evidence will unlikely be in 
the form of a single-centre RCT although a multi-centre randomised-feasibility study may 
present more favourable findings. 
2.5.2 LIMITATIONS  
 
The studies included in this review consist of very low-grade evidence, as assessed using 
GRADE, and all of the included studies are retrospective cohort studies. Though some of 
these studies adjusted for the presence of major confounders, there is likely still bias as a 
result of confounding factors within and between each study. The exact population and 
indication for intervention differed between the studies and therefore it is difficult to draw 
exact comparisons between the outcomes of each study. This resulted in a limitation in 
performing a meta-analysis of the included studies and any conclusions drawn may still be 
limited due to confounding. We calculated odds ratios, confidence intervals and relative risks 
for the results of each study, but these may be misleading and must be interpreted with 
caution. We aimed to address a shortfall in reviews describing the efficacy of either the 
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Arabin pessary or progesterone to prevent PTB in women with prior cervical excision, but 
unfortunately studies are still lacking and therefore we could not address this within our 
review. As a result, we were also unable to determine the comparative efficacy of the three 
interventions we aimed to review. 
2.6      CONCLUSION 
 
The findings of this review indicate that women with prior cervical surgery that receive a 
cerclage during pregnancy are at increased risk of PTB prior to both 34- and 37-weeks 
relative to those that do not receive an intervention. This is likely due to the increased risk of 
PTB in women with a CL <25mm relative to those without cervical shortening. There is a 
lack of studies considering the management of women with prior cervical surgery during 
pregnancy. Further retrospective cohort studies comparing cerclage, pessary and 
progesterone to one another are required to determine the comparative efficacy of each in 
preventing PTB in women with prior cervical surgery. Prospective studies would also assist 


















CHAPTER 3 - CERCLAGE, PESSARY OR PROGESTERONE TO PREVENT PRETERM 
BIRTH IN WOMEN WITH PRIOR CERVICAL SURGERY 
3.1 BACKGROUND 
 
Women with prior cervical surgery, indicated following findings of moderate-severe cervical 
intraepithelial neoplasia, are at an increased risk of sPTB and this risk is present in all post-
surgical pregnancies32. Following a KCB, the risk of PTB is greater in subsequent 
pregnancies relative to the risk following a LLETZ procedure19, this may be owing to the 
greater volume of tissue excised during a KCB. However, collectively it is estimated that 
around 2.5% of UK PTBs per year are a result of surgical procedures to the cervix21. 
Theories suggest the PTB risk may be a result of a weakening in the mechanical strength of 
the cervix due to post-surgical regeneration producing an inferior quality of tissue24. Another 
theory suggests the removal of glands that secrete the cervical mucus plug leave the cervix 
vulnerable to ascending infection which further increases the risk of PTB23. Managing this 
risk is vital to prevent poor neonatal outcomes as PTB remains the leading cause of 
neonatal morbidity and mortality worldwide8.  
Preventative interventions in the form of either vaginal cerclage, VP or an Arabin pessary, 
are indicated following the findings of a mid-trimester CL <25mm15, 67. Cerclage has been 
used historically in the prevention of PTB in high-risk women but the results of various 
studies surrounding its efficacy remain contradictory. A review by Alfirevic et al.69 concluded 
no benefit of cerclage for women with a short cervix but Jarde et al.72 disputed these 
findings. The subgroup analysis within this review demonstrated efficacy of cerclage in 
reducing PTB <37 weeks in this cohort. Neither review was able to perform any analysis for 
women with prior cervical surgery. Similarly, the evidence surrounding the use of 
progesterone in asymptomatic high-risk women is conflicting with some studies 
demonstrating efficacy in prevention of PTB76-78 and others disputing these findings80, 81. The 
2021 EPPPIC study performed a large-scale individual participant meta-analysis and 
demonstrated the efficacy of progesterone in preventing PTB <34 weeks79. However, like all 
studies of both progesterone and the Arabin pessary, this study incorporated a broad high-
risk cohort without subgroup analysis for participants with cervical surgery.  
There remains no consensus as to which intervention offers the greatest efficacy in the 
prevention of PTB in women with prior cervical surgery. The systematic review conducted 
within this thesis, highlighted the need for further studies to determine the comparative 
efficacy of interventions to prevent PTB in women with prior cervical surgery. This is 
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supported by the findings of Grabovac et al.123 and Alfirevic et al.69 This retrospective cohort 
study aims to address the lack of evidence surrounding the use of cerclage, pessary and 
progesterone in this cohort of women.  
3.2 METHODS 
 
3.2.1 REFERRAL AND SCREENING 
 
This is a retrospective cohort study of all women with prior cervical surgery attending the 
specialist PTB prevention clinic at Liverpool Women’s Hospital (LWH) between 2008-2020. 
Patients are initially screened for risk factors associated with PTB at their first antenatal 
appointment with a midwife. Any women identified as high risk as defined by; previous KCB, 
single LLETZ >10mm depth, ≥2 previous LLETZ procedures, previous PPROM or sPTB 
before 34 weeks’ gestation, are referred to the specialist PTB prevention clinic on booking 
their pregnancy. Some women may be referred to the clinic following an incidental finding of 
a short cervix during routine antenatal care screening or on symptomatic presentation to the 
maternity assessment unit. Gestational age is confirmed by the measurement of crown-rump 
length at the booking scan. The first attendance at the specialist PTB prevention clinic 
determines whether the patient has any further risk factors for PTB, and how these were 
managed in previous pregnancies. This appointment usually takes place around 16 weeks’ 
gestation, though high-risk women planning for history-indicated cerclage will be seen from 
12 weeks. Routine transvaginal ultrasound screening of CL for high risk women also typically 
takes place from around 16 weeks and continues up to 28-weeks’ gestation. This includes 
the identification of a short cervix or the presence of any funnelling or cellular debris 
(amniotic fluid sludge) that may indicate an imminent risk of PTB. Patients return to follow-up 
appointments every 2-4 weeks, unless any significant cervical shortening has been identified 
between appointments or the patient becomes symptomatic, in which case they are seen 
more regularly, usually every 1 or 2 weeks. Patients can also attend more regularly if they 
are particularly anxious about the pregnancy outcome, and may have experienced 
significantly adverse outcomes in a previous pregnancy, usually with certain gestations 
providing anxiety triggers and increased reassurance is built into their care. 
3.2.2 INTERVENTION 
 
The LWH baseline for intervention, in line with the national guidelines, is a CL <25mm with 
or without the presence of funnelling or cell debris, though funnelling and sludge can indicate 
a more urgent requirement for intervention. Some women at a particularly high risk of PTB 
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may require intervention prior to CL screening, these patients can be seen as early as 10 
weeks’ gestation. In 2019, the LWH guidance changed to include the use of omega-3 dietary 
supplementation (Omacor) to aid the prevention of PTB<37 weeks, following a Cochrane 
evidence update107. This is offered at a dose of 2000mg once per day to all women aside 
from those already taking adequate supplements, such as those with a vegetarian diet. 
Should a patient require treatment to prevent PTB, the options of vaginal cerclage, VP and 
Arabin pessary are discussed. Patients who have had successful treatment with one of the 
interventions in a previous pregnancy will often receive the same intervention in subsequent 
pregnancies. If any one of these interventions fails and the patient experiences further 
cervical shortening between appointments, an additional preventative intervention may be 
added. Alternatively, should a patient struggle to tolerate a particular intervention due to side 
effects or otherwise, they may opt to switch to a different intervention. In cases of an 
extremely short cervix with funnelling, the siting of a vaginal cerclage is often the first-choice 
management. Similarly, patients presenting with a dilated cervix or bulging membranes may 
be deemed suitable to receive an emergency cerclage. Some patients attend clinic with a 
transabdominal cerclage sited prior to pregnancy often secondary to previous failed 
treatment or radical trachelectomy, these women are followed-up in an identical manner to 
those without a TAC. In cases of cervical shortening despite the placement of a TAC, 
patients can receive further intervention in the form of either progesterone or an Arabin 
pessary and where cervical dilation results in bulging membranes, a vaginal cerclage may 
be sited. 
3.2.2.1 VAGINAL CERCLAGE  
 
The McDonald technique for cerclage is used at LWH for those patients that require 
intervention and opt for a stitch. Regional anaesthesia is administered prior to the procedure. 
With the patient placed in the lithotomy position, using Allis’ or Babcock’s forceps, the cervix 
is gently pulled towards the vaginal opening138. Using a mayo needle, a monofilament or 
braided suture is inserted as superiorly as possible towards the level of the cervicovaginal 
junction. This is described as a purse-string suture as the internal os is closed by the tight 
stitch138. A handful of patients that are followed-up in the specialist PTB prevention clinic at 
LWH receive a Shirodkar cerclage, generally inserted in another centre prior to attending the 
LWH specialist PTB prevention clinic. The Shirodkar technique is more complex and 
requires the insertion of a suture more superiorly at the level of the cardinal ligaments, again 
under regional anaesthesia. Two incisions are made, one around the cervix at the level of 
the internal os and another posteriorly139. The anterior vaginal wall is opened and the 
bladder is reflected superiorly. Using either nylon or mersilene tape, a stitch is placed around 
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the cervix and a knot is tied anteriorly. The two incisions are then closed139. All patients 
undergo a TVUSS at each follow-up visit and this is used to assess both the position of the 
cerclage and any cervical shortening that may indicate a need for further intervention. 
3.2.2.2 VAGINAL PROGESTERONE 
 
Women that opt for treatment with VP are prescribed 200mg Cyclogest pessaries to insert 
once per night. In some cases, patients may already take progesterone 400mg as 
prescribed by the fertility clinic prior to referral to the specialist PTB prevention clinic and it is 
advised to reduce the progesterone dose to 200mg after the first specialist PTB prevention 
clinic appointment. On the prescription of VP pessaries, patients are informed of the 
insertion technique. It is recommended to insert the pessary at night while in either a 
squatting position or laid down. A lubricant gel can be used if the patient experiences any 
discomfort. Following insertion, patients should remain laid down for at least 30 minutes to 
avoid displacement. For this reason, inserting the pessary before going to bed is 
recommended. 
3.2.2.3 ARABIN PESSARY 
 
Patients that opt for an Arabin pessary have them sited by a trained specialist using the 
technique set-out by Arabin et al.83 Prior to the siting of the pessary, a vaginal examination is 
performed to determine the cervical position and identify any potential obstructions such as 
anatomical abnormalities. The pessary is then compressed and, following the application of 
lubricant, inserted into the vagina towards the posterior fornix at a 45-degree angle. Once at 
the correct level, the pessary can be released to assume its position around the cervix. 
Following placement, the clinician then ensures a central position of the pessary by running 
the examining fingers around the cervix82. Incorrect siting of the pessary can result in 
displacement or discomfort to the patient and therefore the position is confirmed both on 
siting and at a follow-up appointment 1-2 weeks later. Following insertion, the pessary can 
be gently advanced more posteriorly to provide further angling of the cervix. At each 
specialist PTB prevention clinic follow-up appointment, the adequacy of the pessary’s 
positioning is assessed and confirmed. Typically, this does not involve vaginal examination 
unless the patient is symptomatic82. Those that receive an Arabin pessary are informed at 
the time of its siting that should PPROM occur, they should attend the hospital and the 
pessary must be removed. The Arabin pessary is routinely removed at 37+0 weeks. Though 
it can be undertaken quickly, the procedure can cause discomfort and patients must be 
informed of this. The cervix is pushed upwards to allow for the insertion of the index finger 
over the inner ring of the pessary at 12 o’clock. Should this fail, the finger can be rotated 
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posteriorly, within the inner ring, to reach the 6 o’clock position and release the pessary. The 
application of downward traction posteriorly then anteriorly allows for the removal of the 
pessary. Alternatively, should both of the aforementioned manoeuvres fail, atraumatic 
scissors can be used to cut the pessary82.  
All women attending the specialist PTB prevention clinic at LWH, who went on to deliver 
between 2008-2020 were screened for inclusion in this retrospective cohort study. All data 
were extracted retrospectively from a database of continuous service evaluation collected 
prospectively. MEDITECH was used to collect the demographic data for each patient. 
Women with singleton pregnancies and prior history of either KCB, single LLETZ or multiple 
LLETZ procedures were included. Exclusions were made for duplicates, missing data, 
patients managed with transabdominal cerclage, multiple pregnancies, prior radical 
trachelectomy, laser procedures, and termination of pregnancy (TOP). Duplicates were 
defined as women who attended clinic for more than one pregnancy within the study period 
and these were identified based on hospital W numbers. The first pregnancy with specialist 
PTB prevention clinic involvement was retained and any subsequent pregnancies were 
excluded due to the increased likelihood of similar outcomes in future pregnancies. Patients 
with a transabdominal cerclage were excluded as this is most commonly sited prior to 
pregnancy as a primary preventative intervention. Multiple pregnancies and radical 
trachelectomy procedures constitute higher risk groups than singletons and women at risk 
due to LLETZ or KCB procedures respectively and therefore these were excluded. Laser 
procedures have not been performed within the trust for over 20 years and thus the data 
surrounding these procedures is less robust and lacks reliability. Any terminations were due 
to fetal abnormalities and therefore this alternate outcome would limit our ability to determine 
the pregnancy outcomes owed to the risk from previous cervical surgeries.   
3.2.3 STATISTICAL ANALYSIS  
 
Initial analyses were performed to assess the association between demographic and clinical 
variables based on the treatment type. These were performed in IBM SPSS statistics version 
26, using Chi-squared and one-way ANOVA tests as appropriate. The impact of 
clinical/demographic factors on each outcome were performed using univariable and 
multivariable generalised linear models. For continuous outcomes, such as birthweight and 
gestation time, identity link function and normal family were assumed. For the PPROM 
outcome, a logistic link and binomial family were assumed. Terms were included in the 
multivariable model using a backwards stepwise approach based on Akaike’s Information 
Criterion. A p-value of 0.05 was used to determine statistical significance throughout. 
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Separate models were performed for those with and without a previous sPTB. All univariable 
and multivariable analyses were performed by Dr Richard Jackson in R (Version 3). 
3.3 RESULTS 
 
Of 1906 women attending the LWH specialist PTB prevention clinic, 607 met the inclusion 
criteria. Following exclusions, 441 cases were identified for analysis (Figure 13). 
 
 
Figure 13: Cases identified for analysis following exclusions 
 
Screened women attending Liverpool women’s hospital PTB 
clinic  
(n = 1906)  
Excluded (n = 166): 
• Duplicates (n = 82) 
• Missing data (n = 54) 
• TAC (n = 13) 
• Multiple pregnancy (n = 11) 
• Trachelectomy (n = 3) 
• Laser (n = 2) 
• TOP (n = 1) 
 
 
No previous sPTB (n = 365) 
 
Cases identified for analysis (n = 441) 
 
Cases with previous cervical surgery (n = 607) 
 
Did not meet inclusion criteria (n = 1299) 




3.3.1 STUDY POPULATION 
 
Table 9 demonstrates the demographic characteristics of the included participants, 
separated based on whether the patient had a previous sPTB <37 weeks. History of cervical 
surgery is presented based on the most significant procedure and therefore where some 
participants have received both a KCB and LLETZ procedure, they have been included 
under the KCB heading. Four hundred and forty-one women with prior cervical surgery were 
included in the analysis, of which 365 had no previous sPTB and 76 had a previous sPTB. A 
total of 105 women delivered prior to 37 weeks constituting around half of the pregnancies in 
women with a previous sPTB and 18% of those without. Of the 105 women receiving 
treatment, 39% (n = 41) delivered before 37 weeks and 23% (n = 24) delivered prior to 34 
weeks. Of the 18 cerclages, only 2 were monofilament sutures and the remaining 16 were 
braided.  
Table 9: demographic characteristics of study participants by previous sPTB 
Data are presented as n (%) or median (IQR) 
Covariate No previous sPTB Previous sPTB Total 
Total                               365 76 441 
Height (cm)  165 (161, 169) 166 (162, 170) 165 (161, 169) 
Weight (kg)  66 (60, 77) 67 (60, 75) 67 (60, 77) 
BMI  24.2 (21.8, 28.3) 24.4 (22.1, 28.25) 24.3 (21.8, 28.35) 
Ethnicity 
   Caucasian 359 (98%) 72 (95%) 431 (98%) 
   Black 1 (0%) 3 (4%) 4 (1%) 
   Asian 2 (1%) 1 (1%) 3 (1%) 
   Mixed 2 (1%) 0 (0%) 2 (0%) 
   Other 1 (0%) 0 (0%) 1 (0%) 
Smoker                          86 (24%) 30 (39%) 116 (26%) 
Age at EDD    32 (29, 35) 32.5 (29, 36) 32 (29, 36) 
Previous cone biopsy                         88 (24%) 7 (9%) 95 (23%) 
Previous single LLETZ                        132 (36%) 57 (75%) 189 (43%) 
Previous multiple LLETZ                        145 (40%) 12 (16%) 157 (36%) 
Uterine abnormality 2 (1%) 1 (1%) 3 (1%) 
Previous PPROM               25 (7%) 25 (33%) 50 (11%) 
Previous late miscarriage (16-23 weeks) 10 (3%) 3 (4%) 13 (3%) 
Gestation at intervention        20.4 (17.7, 24) 18.2 (16.5, 21.9) 20.1 (16.6, 23.6) 
Received intervention 67 (18%) 38 (50%) 105 (24%) 
Intervention 
   None                298 (82%) 38 (50%) 336 (76%) 
   Vaginal Cerclage                    13 (4%) 5 (7%) 18 (4%) 
   Progesterone                        35 (10%) 22 (29%) 57 (13%) 
   Arabin pessary                      32 (9%) 16 (21%) 48 (11%) 
Shortest CL 




Table 10 demonstrates the demographic characteristics and outcome variables based on the 
treatment received by each participant. Seventeen participants receiving more than one 
intervention during pregnancy were excluded. Any statistically significant differences are 














   15-20mm                       32 (9%) 12 (16%) 44 (10%) 
   20-25mm                          61 (17%) 21 (28%) 82 (19%) 
   25-30mm                         93 (25%) 14 (18%) 107 (24%) 
   30-35mm                          72 (20%) 8 (11%) 80 (18%) 
   >35mm                         70 (19%) 4 (5%) 74 (17%) 
Omacor use 27 (7%) 8 (11%) 35 (8%) 
Gestation at delivery 
   <24 weeks 4 (1%) 1 (1%) 5 (1%) 
   <28 weeks 9 (2%) 4 (5%) 13 (3%) 
   <32 weeks 17 (5%) 12 (16%) 29 (7%) 
   <34 weeks 26 (7%) 21 (28%) 47 (11%) 
   <37 weeks 66 (18%) 39 (51%) 105 (24%) 
Onset of labour 
   Spontaneous 156 (43%) 47 (62%) 203 (46%) 
   Induced 138 (38%) 18 (24%) 156 (35%) 
   Pre-labour caesarean section 71 (19%) 11 (14%) 82 (19%) 
Mode of delivery 
   Vaginal  248 (68%) 56 (74%) 304 (69%) 
   C-section 117 (32%) 20 (26%) 137 (31%) 
PPROM 21 (6%) 12 (16%) 33 (7%) 
Late miscarriage (16-23 weeks) 1 (0%) 0 (0%) 1 (0%) 
Livebirth 360 (99%) 75 (99%) 435 (99%) 
Stillbirth 2 (1%) 1 (1%) 3 (1%) 
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Table 10: Demographic characteristics of study participants by treatment received 
Data are presented as n (%) or median (IQR) 
† One-way ANOVA ‡ Chi-squared  
Covariate Cerclage Pessary Progesterone No treatment p 
Total                               10 38 41 336  






165 (161, 169) 0.634 † 
Weight (kg)  70 (67, 81) 63 (60, 71) 70 (61, 80) 67 (60, 76) 0.424 †  






24.4 (22, 28.4) 0.201 † 
Ethnicity   
   Caucasian 10 (100%) 36 (95%) 41 (100%) 328 (98%) 0.452 ‡  
   Black 0 (0%) 2 (5%)  0 (0%) 1 (0%) 0.006 ‡ 
   Asian 0 (0%) 0 (0%)  0 (0%) 4 (1%) 0.784 ‡ 
   Mixed 0 (0%) 0 (0%)  0 (0%) 2 (1%) 0.912 ‡ 
   Other 0 (0%) 0 (0%)  0 (0%) 1 (0%) 0.966 ‡ 
Smoker                          8 (73%) 9/37 (24%) 10/38 (26%) 86/335 (26%) 0.002 ‡ 
Age at EDD    33 (29, 38) 31 (29, 35) 34 (31, 39) 32 (29, 35) 0.188 †  
Previous cone biopsy                         2 (20%) 7 (18%) 6 (15%) 76 (23%) 0.683 ‡ 
Previous single LLETZ                        4 (40%)  18 (47%) 24 (59%) 135 (40%) 0.142 ‡ 
Previous multiple LLETZ                        4 (40%)   13 (34%)  11 (27%) 125 (37%) 0.608 ‡ 
Uterine abnormality 0 (0%) 0 (0%) 0 (0%) 3 (1%) 0.849 ‡ 
Previous sPTB  5 (50%) 11 (29%) 17 (42%)  38 (11%) 0.000 ‡ 
Previous PPROM               3 (30%) 7 (18%) 10 (24%) 28 (8%) 0.002 ‡ 
Previous late miscarriage (16-23 
weeks) 
4 (40%) 1 (3%) 0 (0%) 7 (2%) 0.000 ‡ 
Gestation at intervention        13.5 
(12.5, 21.3) 
19 (16, 23) 22 (17, 24.3) - 0.000 † 
Shortest CL   
   <15mm                 1 (10%) 21 (55%) 10 (24%) 5 (2%) 0.000 ‡ 
   15-20mm                       2 (20%) 8 (21%) 12 (29%) 13 (4%) 0.000 ‡ 
   20-25mm                           5 (50%) 8 (21%) 9 (22%) 44 (13%) 0.005 ‡ 
   25-30mm                         1 (10%) 1 (3%) 6 (15%) 99 (29%) 0.001 ‡ 
   30-35mm                          1 (10%) 0 (0%) 1 (2%) 91 (27%) 0.000 ‡ 
   >35mm                          0 (0%) 0 (0%)  3 (7%) 84 (25%) 0.000 ‡ 
Omacor use 2 (20%) 0 (0%)  9 (22%) 20 (6%) 0.000 ‡ 
Gestation at delivery   
   <24 weeks 0 (0%) 2 (5%) 1 (2%) 2 (1%) 0.068 ‡ 
   <28 weeks 0 (0%) 5 (12%) 2 (2%) 4 (1%) 0.000 ‡ 
   <32 weeks 0 (0%) 6 (16%) 5 (12%) 15 (5%) 0.011 ‡ 
   <34 weeks  1 (10%) 8 (21%) 9 (22%) 23 (7%) 0.001 ‡ 
   <37 weeks  1 (10%) 13 (34%) 16 (39%) 64 (19%) 0.005 ‡ 
Onset of labour   
   Spontaneous 5 (50%) 23 (61%) 20 (49%) 146 (44%) 0.233 ‡ 
   Induced  3 (30%) 8 (21%) 15 (37%) 125 (37%) 0.257 ‡ 
   Pre-labour caesarean section  2 (20%) 7 (18%) 6 (15%) 65 (19%) 0.909 ‡ 
Mode of delivery   




3.3.2 UNIVARIABLE ANALYSIS 
 
The results of the univariable analysis are included for each outcome in the table below 
(Table 11). Results are separated based on history of previous PTB. Gestation time is listed 
in weeks and birthweight in grams. Smoking refers to all current and past smokers. Results 
are presented in terms of model estimates (est) and standard error (se). 
3.3.2.1 PREVIOUS SPONTANEOUS PRETERM BIRTH 
 
In women with prior cervical surgery and a previous sPTB, history of a single previous late 
miscarriage is significantly associated with a shortened gestation time of over 5 weeks (est: -
5.07 (2.275); p-value 0.029) and, in turn, a lower birthweight can be seen (est: -980.96 
(474.567); p-value 0.042). None of the 3 interventions, vaginal cerclage, progesterone or 
Arabin pessary demonstrated statistical significance against any of the outcome measures in 
these women. In addition, none of the other clinical or demographic factors were associated 
with any of the 3 clinical outcomes.   
3.3.2.2 NO PREVIOUS SPONTANEOUS PRETERM BIRTH 
 
In women with cervical surgery and no previous sPTB, VP is associated with an increased 
risk of PPROM (est 2.17 (0.65); p-value 0.001). Below a CL of 35mm, the gestation time 
decreases with every 5mm decrease in CL. Vaginal cerclage reduces the gestation time by 
3.5 weeks (est -3.45 (0.907); p-value <0.001), Arabin pessary by 2.5 weeks (est -2.52 
(0.591); p-value <0.001) and progesterone by 1.5 weeks (est -1.51 (0.576); p-value 0.009). 
As expected, birthweight follows the same trend with cerclage having the greatest impact, 
followed by pessary then progesterone, on the reduction of birthweight. Women that 
received no intervention during pregnancy have a longer gestation time (est 1.67 (0.396); p-
value <0.001) and therefore a higher birthweight (est 328.27 (88.705); p-value <0.001). 
Furthermore, omega-3 supplementation prolongs gestation by 3 weeks (est 3.1 (0.637); p-
value <0.001).  
 
   C-section 5 (50%)  9 (24%) 14 (34%) 102 (30%) 0.410 ‡ 
PPROM  0 (0%)  5 (13%) 5 (12%) 19 (6%) 0.126 ‡ 
Late miscarriage (16-23 weeks)  0 (0%) 0 (0%) 0 (0%) 1/334 (0%) 0.966 ‡ 
Livebirth 10 (100%) 38 (100%) 40 (98%) 331 (99%) 0.798 ‡ 
Stillbirth 0 (0%) 0 (0%) 1 (2%) 2 (1%) 0.540‡ 
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Table 11: Univariable analysis of three clinical outcomes; PPROM, Birthweight (grams), Gestation time (weeks) in women with and without a previous sPTB 
Data are presented as model estimates (est) and standard error (se) with associated p-values 
 Previous sPTB No previous sPTB 
 PPROM Birthweight Gestation time PPROM Birthweight Gestation time 
Covariate                      est (se) P est (se) P est (se) P est (se) P est (se) P est (se) P 
Height (cm)                           -0.03 (0.048)      0.478  10.38 
(14.547)     
0.478  -0.03 
(0.069)  
0.658  0 (0.036)          0.984  5.45 
(5.963)       
0.361   -0.01 
(0.027)  
0.78    
Weight (kg) -0.02 (0.023)      0.381  6.51 
(5.448)       
0.236  0.01 
(0.026)   
0.797  0 (0.015)          0.957  7.11 
(2.528)       
0.005   0 (0.011)      0.779   
BMI                                 -0.04 (0.062)      0.526  16.55 
(16.151)     
0.309  0.03 
(0.077)   
0.668  0 (0.042)          0.944  15.71 
(6.934)      
0.024   0 (0.031)      0.906   
Smoking                             0.08 (0.64)        0.898  -317.97 
(193.743)  
0.105  -0.6 
(0.94)    
0.529  0.94 (0.46)        0.042  -109.65 
(88.584)   
0.217   -0.22 
(0.402)  
0.59    
Age at EDD                          -0.06 (0.066)      0.325  24.33 
(19.484)     
0.216  0 
(0.094)      
0.979  -0.1 
(0.055)       
0.079  13.61 
(9.049)      
0.133   0.08 
(0.041)   
0.038   
Single Cone biopsy                        -16.01 
(1495.296)  
0.991  -1.47 
(329.17)     
0.996  0.53 
(1.581)   
0.738  -0.31 
(0.57)       
0.592  83.51 
(88.516)     
0.346   0.73 
(0.401)   
0.068   
Multiple cone biopsy - - - - - - -12.84 
(1455.398)  
0.993  611.25 
(711.437)   
0.391   2.12 
(3.267)   
0.518   
No. of LLETZ 1                   16.89 
(2465.326)   
0.995  -5.05 
(335.411)    
0.988  -0.36 
(1.604)  
0.821  0.36 
(0.793)       
0.653  -71.05 
(120.323)   
0.555   -0.49 
(0.548)  
0.37    
No. of LLETZ 2                  17.59 
(2465.326)   
0.994  97.14 
(412.312)    
0.814  -1.02 
(1.936)  
0.6    0.29 
(0.809)       
0.722  -9.9 
(123.212)     
0.936   -0.46 
(0.558)  
0.408   
No. of LLETZ 3                       0 (6972.994)       1      -589.86 
(894.43)   
0.512  -4.73 
(4.28)   
0.272  0.61 
(1.267)       
0.632  -159.24 
(224.53)   
0.479   -0.73 
(1.031)  
0.479   
Uterine Abnormality         -13.91 
(1455.398)  
0.992  860.44 
(828.158)   
0.302  3.22 
(3.999)   
0.423  -12.78 
(1029.121)  
0.99   -146.55 
(503.91)   
0.771   0.8 
(2.321)    
0.731   
Previous PPROM               0.45 (0.645)       0.483  -103.94 
(205.421)  
0.614  -0.88 
(0.969)  
0.368  0.38 
(0.774)       
0.619  -411.42 
(145.834)  
0.005   -1.55 
(0.673)  
0.022   




0.994  -980.96 
(474.567)  
0.042  -5.07 
(2.275)  
0.029  -14.8 
(1318.727)   
0.991  43 
(254.538)       
0.866   0.75 
(1.106)   
0.499   
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Multiple previous late 
miscarriages  
- - - - - - -14.8 
(3956.18)    
0.997  80.5 
(712.708)     
0.91    0.38 
(3.28)    
0.907   
No intervention                -0.34 (0.637)      0.597  86.99 
(192.463)    
0.653  0.49 
(0.914)   
0.59   -0.53 
(0.48)       
0.267  328.27 
(88.705)    
<0.001  1.67 
(0.396)   
<0.001  
Received intervention                              0.4 (0.637)      0.531  -137.68 
(191.981)  
0.476  -0.72 
(0.911)  
0.431  -0.49 
(1.044)      
0.638  68.97 
(144.798)    
0.634   -0.34 
(0.654)  
0.599   
Vaginal Cerclage                    -15.97 
(1769.258)  
0.993  185.76 
(383.168)   
0.629  1.47 
(1.838)   
0.425  0.86 
(0.484)       
0.075  -460.78 
(95.721)   
<0.001  -1.95 
(0.431)  
<0.001  
Progesterone                        0.25 (0.673)       0.716  -287.55 
(210.973)  
0.177  -1.85 
(0.986)  
0.064  2.17 (0.65)        0.001  -821.92 
(195.987)  
<0.001  -3.45 
(0.907)  
<0.001  
Arabin pessary                      0.77 (0.691)       0.263  -76.47 
(233.835)   
0.745  -0.33 
(1.122)  
0.769  1.19 
(0.547)       
0.03   -351.71 
(130.432)  
0.007   -1.51 
(0.576)  
0.009   
Shortest CL (15-20 mm)                          0.08 (0.878)       0.927  -301.12 
(314.202)  
0.341  -1.19 
(1.469)  
0.422  0.1 (0.768)        0.9    -578.42 
(132.101)  
<0.001  -2.52 
(0.591)  
<0.001  
Shortest CL (20-25 mm)                          -1.07 (0.938)      0.253  204.73 
(264.916)   
0.442  1.31 
(1.272)   
0.308  0.42 
(0.719)       
0.556  339.99 
(166.46)    
0.042   1.97 
(0.757)   
0.01    
Shortest CL (25-30 mm)            -0.61 (0.954)      0.52   254.49 
(293.051)   
0.388  1.8 
(1.407)    
0.205  -0.85 
(0.794)      
0.284  681.62 
(141.957)   
<0.001  2.98 
(0.653)   
<0.001  
Shortest CL (30-35 mm)               -0.77 (1.212)      0.527  309.92 
(364.656)   
0.398  2.11 
(1.671)   
0.211  -0.99 
(0.736)      
0.178  788.92 
(133.002)   
<0.001  3.03 
(0.609)   
<0.001  
Shortest CL (>35 mm)                   -16.39 
(1978.09)   
0.993  785.31 
(451.239)   
0.086  3.25 
(2.166)   
0.137  -1.03 
(0.793)      
0.196  705.62 
(138.442)   
<0.001  3.52 
(0.634)   
<0.001  
Omacor                              -0.3 (1.119)       0.788  470.98 
(305.228)   
0.127  2.27 
(1.468)   
0.126  -1.42 
(0.892)      
0.112  695.58 
(139.149)   
<0.001  3.1 






3.3.3 MULTIVARIABLE ANALYSIS 
 
The results of the multivariable analyses are included for each outcome in the tables below. 
3.3.3.1 PREVIOUS SPONTANEOUS PRETERM BIRTH 
 
Table 12 shows the results of the multivariable analysis for each outcome in women with a 
previous sPTB. For this cohort, the estimated gestation at delivery is 36.31 weeks. For 
gestation time, the number of previous late miscarriages, progesterone and omacor all have 
a significant impact. The use of omacor supplementation prolongs gestation with an 
estimated increase of 4 weeks (est 4.03 (1.53); p-value 0.011), an increase in birthweight 
can also be seen (est 757.71 (326.18); p-value 0.023). It is the only variable with a positive 
impact on gestation time or birthweight in this subgroup. Intervention with progesterone is 
associated with a 3 week decrease in gestation time (est -3.15 (1.059); p-value 0.004). This 
effect can also be seen in women with a previous late miscarriage (est -4.6 (2.282); p-value -
0.048). Given the relatively small data set, no factors were found to have a significant impact 
on PPROM. There is no impact of LLETZ in any model. Neither vaginal cerclage nor Arabin 
pessary had any significant effect on any outcome. 
Table 12: Multivariable analysis of women with a previous sPTB 
  BIRTHWEIGHT GESTATION TIME 
 est (se) P est (se) P 
(Intercept) 2211.91 (504.897)  <0.001 36.31 (1.39)  <0.001 
Weight (kg) 7.25 (5.229)       0.17  -  - 
Smoking                 -257.97 (189.789)  0.179  - -  
Single previous late miscarriage -1017.96 (482.189) 0.039 -4.6 (2.282)  0.048 
Progesterone               -552.86 (229.937)  0.019 -3.15 (1.059) 0.004 
Omacor                   757.71 (326.18)    0.023 4.03 (1.54)   0.011 
No. of LLETZ 1        98.28 (321.267)    0.761 0.27 (1.508)  0.857 
No. of LLETZ 2    294.8 (404.246)    0.468 0.31 (1.844)  0.868 





3.3.3.2 NO PREVIOUS SPONTANEOUS PRETERM BIRTH 
 
Table 13 shows the results for each patient without a previous sPTB. The estimated 
gestation time is 33.62 (1.436) weeks in this cohort and this is shorter than that of women 
with a previous sPTB. Previous PPROM and CL both have a statistically significant impact 
on gestation time. Below 35mm, gestation time shortens for each 5mm decrease in CL. A 
history of PPROM decreases the gestation time by over a week (est -1.42 (0.681); p-value 
0.037). Cerclage, pessary and progesterone demonstrated no statistically significant impact 
on gestation time or birthweight. However, cerclage is associated with an increased risk of 
PPROM (est 2.16 (0.723); OR 8.69 (2.104-35.869); p-value 0.003), although the wide 
confidence interval raises uncertainty surrounding the extent of this risk. For birthweight; 
smoking, age, number of previous PPROM and CL are all statistically significant. Again, 


























Table 13: Multivariable analysis of women without a previous sPTB 
  PPROM BIRTHWEIGHT GESTATION TIME 
                       est (se) 
OR 
(95% 
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This retrospective cohort study demonstrates the uncertainty surrounding PTB prevention in 
women with prior excisional procedures of the cervix. Women that do not require an 
intervention are lower risk and therefore have a prolonged gestation relative to women that 
receive an intervention. Current practice using either cerclage, pessary or progesterone 
confers no significant benefit in the prolonging of gestation time. Our analysis shows that 
progesterone may, in fact, be less effective than cerclage or pessary in this cohort. Our 
findings for cerclage are supported by both the systematic review undertaken within this 
thesis and the review by Grabovac et al.123 The PECEP trial is the only multicentre 
randomised study to support the use of the Arabin pessary for short cervix indications89. 
However, this is not supported by our study or the findings of the RCTs by Nicolaides et al.87 
and Hui et al.88 The differences in these results may be due to the inclusion of cervical 
surgery participants in our study and in the study by Nicolaides et al.87 constituting 17% (n = 
159/932) of the cohort, but the exclusion of these women from the PECEP trial. The 
OPPTIMUM study80 demonstrated no efficacy of progesterone in women with a short cervix. 
Including women with prior cervical surgery within a broad risk cohort may have added to the 
heterogeneity of the study population and weakened the estimated overall benefit of 
progesterone in other high-risk groups. It is unclear precisely how many participants within 
this study had prior cervical surgery and therefore it is not possible to determine the extent of 
this impact on results. This highlights the need for women with prior cervical surgery to be 
studied as a separate cohort to women at high risk of PTB with a mid-trimester short cervix 
due to other indications. The 2021 EPPPIC study79 included participant data from 
OPPTIMUM and supported the use of progesterone in women with a short cervix. This 
further supports the assertion that interventions may have varying efficacy in different risk 
cohorts. 
Our understanding of the mechanisms leading to PTB is limited. The results of this study 
suggest that there may be differing mechanisms leading to cervical shortening and 
subsequent PTB in women with a mid-trimester short cervix following cervical surgery 
compared to other high-risk groups. This may explain the varying efficacy of interventions in 
different high-risk cohorts. Alternatively, the mechanisms by which the interventions prevent 
PTB may be impeded in women with cervical surgery due to the loss of cervical tissue. The 
pharmacodynamics of progesterone are not well understood in women with a short cervix. 
However, studies suggest that the administration of VP exerts only local anti-inflammatory 
effects and the impact on systemic progesterone concentration is limited140. Further studies 





efficacy per cohort. In addition, the rates of Arabin pessary displacement are higher in 
women with prior cervical surgery, most significantly in those with a previous KCB85, and this 
may reduce its effect in this group. If there is inadequate cervical tissue to correctly site the 
pessary or provide sufficient posterior angling of the cervix, this could reduce the efficacy of 
the pessary in preventing PTB.  
Unfortunately, due to the limited cohort of participants that experienced PPROM, we were 
unable to draw many conclusions for this outcome. However, cerclage can be seen to cause 
an increased risk of PPROM. This may be due to the introduction of infection which, as with 
any surgical procedure, is a known risk associated with the siting of a cerclage69. Another 
key finding was the greater than 4-week reduction in gestation time in women with a 
previous late miscarriage. Women with a previous mid-trimester loss are a known risk group 
and present a high-risk subgroup in women with previous cervical surgery and a prior sPTB. 
3.4.1 IMPLICATIONS FOR PRACTICE 
 
Our findings do not support the use of vaginal cerclage, pessary or VP to prevent PTB in 
women with cervical surgery. A large-scale multicentre RCT is required to confirm these 
findings and inform future practice. Given the ongoing uncertainty surrounding the 
management of these women and the lack of an effective intervention, screening may also 
present little benefit. Women with prior cervical surgery that develop a mid-trimester CL 
<25mm are a higher risk cohort than those with surgery alone. The identification of these 
women, whilst unable to offer an effective intervention to prevent PTB, does not meet the 
Wilson and Jungner screening criteria141. Further to this, not only is screening costly, but it 
may induce patient anxiety and cause an increase in stress levels during pregnancy. This is 
an independent risk factor for sPTB102. This raises questions for future practice and the most 
appropriate follow-up and counselling of women with previous cervical surgery. 
Our results support the findings of the latest Cochrane review107 in supporting the use of 
omega-3 supplementation to prolong pregnancy. This effect can be seen in women with prior 
cervical surgery and a previous PTB and therefore we support the continued use of Omacor 
in these women.  
3.4.2 STRENGTHS AND LIMITATIONS 
 
This study is the only study to compare the efficacy of interventions to prevent PTB in 
women with prior LLETZ or KCB of the cervix. Previously, several published retrospective 





have compared the efficacy to that of the Arabin pessary or VP. The results presented in this 
study are valuable in guiding future research.   
The main limitation of this study is the retrospective design and the consequent risk of bias 
due to confounding. Despite stratification of data based on the most significant confounding 
factor, previous sPTB, there may still be presence of bias. Therefore, large multicentre RCTs 
are necessary in order to confirm our findings. A further limitation is the lack of neonatal 
outcomes due to our inability to obtain ethical approval, secondary to covid-related 
restrictions on new student projects, for the collection and use of neonatal outcomes and this 
limited our ability to present a complete core outcome set. Future studies should consider 
the impact of these interventions on neonatal outcomes. However, the most common cause 
of neonatal morbidity and mortality is PTB and therefore these outcomes are closely linked 
to gestation at delivery.  
Suture material may affect the efficacy of cerclage in preventing PTB. A study by Kindinger 
et al.68 found the use of a monofilament suture was more beneficial than a braided suture for 
women with cervical surgery. Our study included predominantly participants with braided 
sutures and this may have affected the overall efficacy of cerclage. Future studies should 




In women with previous cervical surgery, current interventions including vaginal cerclage, 
Arabin pessary and VP are ineffective in preventing PTB. Cerclage increases the risk of 
PPROM in women with cervical surgery and a previous sPTB. Large multicentre RCTs are 
required to confirm the findings of our study.  
3.6 ETHICAL APPROVAL 
 
Research ethics committee approval is in place for the collection and use of the specialist 
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CHAPTER 4 - DISCUSSION 
4.1 MAIN FINDINGS 
 
The studies undertaken within this thesis have highlighted some of the key issues related to 
the management of women with prior cervical surgery. Firstly, there is a paucity of research 
which specifically determines the risk of PTB in a population with cervical surgery. Rather, 
most evidence for the management of this group comes from their inclusion in a mixed high-
risk population with other conditions that predispose to PTB including previous PTB and 
short cervix indications. Only 6 published cohort studies have considered the use of cerclage 
and there are no studies considering the use of either pessary or progesterone in this cohort 
alone. Furthermore, there are no published studies comparing the efficacy of these 
interventions to one another in the prevention of sPTB for women with prior excisional 
surgery, nor are there any studies with a prospective design. The systematic review within 
chapter 2 demonstrates this lack of evidence and highlighted the urgent requirement for 
further research in this area.  
In addition, our cohort study (chapter 3) demonstrated no statistically significant benefit of 
cerclage, pessary or progesterone in prolonging gestation in women with previous cervical 
surgery. Furthermore, cerclage can be seen to cause an increase in the risk of PPROM. In 
women with the additional risk of a previous sPTB, progesterone is associated with a 
decrease in gestation time to delivery. The studies within our systematic review did not 
support the use of cerclage for women with previous cervical surgery. Our study is the first to 
extend these findings to include pessary and progesterone and therefore caution should be 
taken in using these three interventions in women with previous cervical surgery. The 
findings of large studies with broad risk cohorts, including women with a short cervix or a 
previous sPTB, are the current basis for the use of these interventions. However, studies of 
this kind may overestimate the efficacy of these interventions in women with previous 
cervical surgery and we have demonstrated a lack of effect in this cohort. Further 
prospective studies are required to confirm our findings and inform future practice. Though a 
two-centre randomised-feasibility study demonstrated inadequate power to perform a multi-
arm comparative RCT in this cohort116, a larger multicentre trial comparing two treatments 
may be more appropriate to confirm our findings. A preceding pilot study may be necessary 
to confirm the feasibility of an RCT in this cohort. 
It cannot be discounted that the results of chapter 3 may be in part due to the identification of 





cervix, are at a higher risk of sPTB than women that do not develop a short cervix42 and 
therefore the apparent lack of effect of cerclage, pessary and progesterone in our study may 
reflect this. In addition, the results of published studies may have been impacted by the 
presence of participants with cervical surgery. This may have served to underestimate the 
effects of interventions in other high-risk cohorts where subgroup analysis had not been 
performed for women with prior excision of the cervix. This could provide an explanation for 
the discrepancies in the results of existing studies surrounding the use of cerclage, Arabin 
pessary and VP to prevent PTB. Up to now, all women with cervical surgery were managed 
following recommendations from large studies69, 72, 76, 80, 89 considering broad high-risk 
cohorts including women with a previous sPTB and short cervix indications. However, our 
lack of understanding of the mechanisms leading to PTB limits our ability to extrapolate 
these results between risk groups. In addition, our results suggest that the mechanisms 
leading to PTB in separate risk cohorts differ and therefore the efficacy of interventions to 
prevent PTB in each group may also vary. As a result, future research in this area should 
stratify for the various risk factors of PTB either through exclusion or subgroup analysis 
within larger studies. This includes separating short cervix indications and participants with 
previous cervical surgery within studies.  
Our cohort study highlights the rate of treatment 18% (n = 67/365), of which 34% (n = 23/67) 
delivered <37 weeks, in women with previous cervical surgery and no prior sPTB. This was 
greater than the 14% (n = 98/725) treatment rate and the 24% (n = 24/98) PTB rate in the 
Kindinger et al.68 study whereby women with previous cervical surgery that developed a 
short cervix received a cerclage. Our cohort had a greater number of women developing a 
short cervix following cervical surgery and this may account for the differences in these 
rates. Both our cohort study and the study by Kindinger et al.68 followed UK NICE guidance 
for the treatment of women at risk of PTB and therefore both provide an accurate 
representation of UK clinical practice. Both studies indicate a lack of effect of cerclage in 
preventing PTB in women with previous cervical surgery. From our cohort of women with 
cervical surgery and no previous sPTB, 82% (n = 298/365) of women received no treatment, 
of which 14% (n = 43/298) had a PTB <37 weeks. This is also greater than the UK 
background population PTB rate of 7.3%135. However, these rates demonstrate a 
multifaceted problem whereby not only are we failing to identify a proportion of high-risk 
women, the current interventions also do not appear effective in preventing its occurrence. In 
our cohort, the treatment rate increased to 50% (n = 38/76) with the additional risk factor of a 
previous sPTB, and of these women 37% (n = 14/38) went on to deliver spontaneously <37 
weeks. Therefore, women with cervical surgery and previous sPTB are at a much greater 





regular follow-up. In addition, of the women with a previous sPTB that had a CL≥25mm and 
received no treatment, 21% (n = 5/24) had a PTB <37 weeks. Currently clinicians are guided 
to consider intervention in women from this cohort with a CL ≥25mm, as per NICE 
guidance15. However, it is unclear how many clinicians offer treatment in these situations 
and given we have demonstrated 21% of these women still deliver preterm, the guidance 
could be optimised to avoid undertreating these women.  
4.1.1 CERCLAGE  
 
Neither the systematic review nor the cohort study undertaken within this thesis support the 
use of cerclage for women with previous cervical surgery. These findings are congruent with 
that of the systematic review by Grabovac et al.123 Not only did cerclage confer no significant 
benefit to the prolonging of pregnancy, we also demonstrated an increased risk of PPROM. 
This may be linked to the introduction of infection on siting the cerclage, a known risk of the 
procedure. The basis for the use of cerclage in women with prior cervical surgery is from 
studies including the Alfirevic et al.69 Cochrane systematic review and the Jarde et al.72 
review. Alfirevic et al.69 were unable to perform subgroup analysis for women with a short 
cervix but Jarde et al.72 demonstrated the efficacy of cerclage in reducing PTB <34 weeks in 
this cohort. Neither study performed subgroup analysis for women with previous cervical 
surgery and therefore the current practice has been inferred by applying data from a generic 
high-risk cohort of women with a short cervix to women with a short cervix due to cervical 
surgery. All studies considering cerclage in women at risk of PTB due to cervical surgery 
alone are retrospective cohort study designs. As highlighted in our systematic review, these 
studies have found no benefit for the use of cerclage in this cohort although results may be 
biased due to confounding and impacted by the identification of the high-risk subgroup of 
women that develop a short cervix and require treatment. 
One issue that must be addressed is the differential efficacy of a cerclage relative to the 
suture material used. Initial studies such as that of Kindinger et al.68 suggest monofilament 
may be preferential to braided sutures in prolonging pregnancy in women with prior cervical 
surgery. Our cohort study had an insufficient population size with a cerclage to draw 
conclusions based on suture material. However, the majority of patients received a braided 
suture and therefore this may have had a direct impact on the efficacy of cerclage in 
preventing PTB in these women. Currently, the C-STICH trial136 comparing cerclage suture 
materials is analysing the results of their RCT and the findings of this study will be useful in 
guiding both future research and future practice for managing high-risk women. In addition, 
cerclage technique is often debated in the literature. The McDonald technique involves the 





stitch is sited more superiorly at the level of the cardinal ligaments. Studies have suggested 
that the Shirodkar technique may be a more beneficial option to the McDonald technique for 
prolonging pregnancy in women with a short cervix142, 143. However, as of yet, there are no 
RCTs. This, again, may present a further consideration for future studies comparing the 
efficacy of interventions to prevent PTB. A protocol has been registered with PROSPERO, 
as of July 2020, for a systematic review and meta-analysis comparing the McDonald and 
Shirodkar cerclage techniques in women at risk of PTB144. The findings of this review may be 
utilised in the planning of future studies of cerclage.  
4.1.2 PESSARY  
 
As discussed in chapter 2, there had been no studies of the Arabin pessary in women with 
previous cervical surgery and therefore the work presented here represents the first study of 
its kind. Similar to the findings of our cohort study for cerclage, the Arabin pessary also 
demonstrated no statistical significance in prolonging gestation time to delivery in women 
with previous cervical surgery. This is contradictory to the findings of the PECEP trial89, that 
demonstrated the efficacy of the Arabin pessary in preventing PTB in women with a mid-
trimester CL <25mm. However, studies of the Arabin pessary have historically presented 
conflicting results and the PECEP trial is the only large-scale study to support the use of the 
Arabin pessary in singleton pregnancies with a short cervix. Two further RCTs demonstrated 
no additional benefit of the Arabin pessary relative to expectant management in this group87, 
88. The differences in these findings may be a result of differences in technique for the siting 
and confirmation of placement of the Arabin pessary. Equally, minor differences in the 
cohorts such as a varying number of participants that have experienced a previous 
spontaneous PTB may limit the strength of findings. We have also presented results to 
suggest the mechanism of PTB in women with a short cervix may vary to that of women with 
previous cervical surgery. This presents another potential confounder in the results of large 
randomised controlled studies that may not have accounted for the number of cervical 
surgery patients and this could further explain the conflicting results in studies. 
The mechanism of action of the Arabin pessary is suggested to be linked to the posterior 
angling of the cervix that reduces the contact of fetal membranes with the vaginal canal in 
conjunction with a re-distribution in the weight of the uterus that relieves the pressure on the 
internal os84. It may also act as an added barrier to infection while providing some cervical 
elongation and a limitation on funnelling at the internal os85. However, in women with prior 
cervical surgery, specifically those with a KCB, the rate of cervical pessary displacement is 
greater and this may affect the overall efficacy of the pessary in this group85. Though the 





for women in other high-risk groups, more consideration should be taken in women with 
previous cervical surgery.  
4.1.3 PROGESTERONE 
  
From the cohort study of LWH data, progesterone has no statistically significant impact on 
the gestation time of women with previous cervical surgery and no prior sPTB and is 
associated with a decrease in gestation time in women with a previous sPTB and cervical 
surgery. Studies suggest that the effect of progesterone is due to a local increase in 
progesterone concentration which inhibits the inflammatory process that causes PTB, there 
are limited effects on the systemic concentration of progesterone140. Our lack of 
understanding of the pharmacodynamics of progesterone limits our ability to explain the 
varying efficacy for PTB prevention seen in published studies of women with a short cervix 
and our cohort study of women with previous cervical surgery. The OPPTIMUM study80 
found no additional benefit of VP in women with a short cervix. However, the number of 
participants with cervical surgery are not detailed within the study results and therefore it is 
not possible to determine the extent of this impact on the overall results. The 2021 EPPPIC 
study incorporated the individual participant data (IPD) of several studies including 
OPPTIMUM80 and supported the use of progesterone in women with a short cervix. This 
may be due to the inclusion of studies with a variety of risk cohorts such as previous sPTB, 
short cervix and IVF within the meta-analysis. Therefore, it is not inconceivable that 
progesterone may be effective in women at risk of PTB due to a previous sPTB or short 
cervix alone yet ineffective in those with previous cervical surgery. Future studies should 
consider these groups as separate cohorts either through subgroup analysis or exclusion 
and incorporation into stand-alone studies. 
4.1.4 17-ALPHA HYDROXYPROGESTERONE CAPROATE 
 
Progesterone in the form of IM 17-OHPC has not been studied for use in women with prior 
cervical surgery. However, in other high-risk cohorts there have been conflicting findings and 
as a result it is not currently recommended in UK guidance15, 67. The 2021 EPPPIC study 
concluded 17-OHPC was effective in reducing PTB <34 weeks and the impact may be 
greatest in women with a short cervix79. This is in contrast to the preceding findings of Winer 
et al.99 in studying the same cohort. We have suggested there may be different mechanisms 
leading to PTB in women with a short cervix relative to women with previous cervical 
surgery. This is based on the findings of our cohort study compared to studies of short cervix 
cohorts69, 72, 79, 89 demonstrating the differing efficacy of interventions in these groups. 





the study by Winer et al.99 finding no benefit in a short cervix cohort. Our study also 
demonstrated the lack of statistically significant effect of VP on prolonging gestation in this 
group and the associated decrease in gestation time in women with a previous sPTB. 
However, previous studies have concluded the mechanism of action of 17-OHPC is likely 
different to that of VP due to the lack of local anti-inflammatory effect that can be seen with 
VP75. Given these findings, there remain questions over whether 17-OHPC could be 
effective in this cohort. 
4.1.5 TRANSABDOMINAL CERCLAGE 
 
One of the theories, explaining why women with previous cervical surgery are at an 
increased risk of PTB, describes a rapid regeneration of collagenous cervical tissue that is 
inferior in quality24. McDonald cerclages are likely sited within this inferior quality cervical 
tissue and this may increase the risk of cerclage failure due to the lacking integrity of the 
cervical tissue. One potential solution to this may be the use of a TAC in these women as 
these are generally sited more superiorly. The MAVRIC trial demonstrated the efficacy of 
TAC in preventing early PTB in women with a previous failed vaginal cerclage in a prior 
pregnancy145. The pregnancy outcomes were more favourable following a TAC than 
following a high or low vaginal cerclage145. Further studies would be required to determine 
the efficacy of TAC in women with previous cervical surgery alone. However, introducing 
TAC in this cohort would present several practical implications in terms of patient 
acceptability, cost and over-treatment of patients. A TAC is typically sited prophylactically 
and given our treatment rate in women with previous LLETZ or cone biopsy without a 
previous sPTB was 18% (n = 67/365), prophylactic intervention may be costly and lead to 
over-treatment of women in this cohort.  
4.1.6 OMEGA-3 FATTY ACIDS 
 
The use of omega-3 supplementation is recommended for women at risk of PTB as per the 
latest Cochrane review surrounding it’s use107. Our retrospective cohort study supported 
these findings for the use of Omacor in women with previous cervical surgery. Our results 
demonstrate Omacor supplementation confers a significant lengthening in gestation time. 
This effect was not seen in any of the three interventions studied. This is the first time this 





4.2 IMPLICATIONS FOR RESEARCH 
 
Historically, women with previous cervical surgery have been studied alongside other 
cohorts of high-risk women, including women with a short cervix or a previous sPTB. 
However, this thesis has highlighted the need for women with previous cervical surgery to be 
studied as a separate cohort to other high-risk women. Our findings suggest that the 
aetiology of PTB in various risk groups may differ and this may directly impact the efficacy of 
interventions to prevent PTB. Therefore, future studies should separate all risk cohorts in 
order to determine the individual efficacy of interventions in those groups. This would also 
avoid the overestimation or underestimation of treatment effect that may occur when 
studying separate risk cohorts together. In addition, further prospective studies are required 
to confirm the findings of our studies. A multicentre RCT would present the highest quality 
evidence in order to confirm these findings and therefore undertaking a multi-centre 
randomised feasibility study would serve to inform future research.  
4.3 IMPLICATIONS FOR PRACTICE 
 
Given the ongoing uncertainty surrounding the optimal management of women with prior 
cervical excision and the retrospective study design within this thesis, it is not possible to 
make recommendations for clinical practice. However, the lack of statistically significant 
effect of cerclage, pessary and progesterone in prolonging gestation cannot be ignored. 
Caution should be used in treating women with cervical surgery as these interventions may 
be less effective than studies suggest for other risk groups. Further prospective studies in 
this area are necessary to confirm our findings and optimise the follow-up and management 
of women with cervical surgery.  
4.4 STRENGTHS AND LIMITATIONS  
 
This thesis is the first to establish the clinical problem we face in managing women with 
previous cervical surgery. There are no studies of the comparative efficacy of interventions 
to prevent PTB in these women and therefore management protocols are drawn from broad 
high-risk cohorts. Unfortunately, due to lacking evidence, the systematic review served only 
to demonstrate the gap in the evidence base and could not draw conclusions surrounding 
the most effective intervention to prevent PTB. Further to this, due to the timescale for 





study does not present the highest quality of evidence. However, it would not have been 
feasible to perform either a prospective study of adequate population size or an RCT.  
Due to the implications of Covid-19 and the subsequent change in university regulations 
regarding the seeking of ethical approval, we were unable to obtain ethical approval for the 
use of neonatal outcomes. In addition, LWH specialist PTB prevention clinic data did not 
consistently contain details of any side effects as a result of the interventions and as a result 
these were not included. This limited our ability to present a full core outcome set and 
therefore the cohort study is lacking some outcomes that may be considered important to 
both parents, when making decisions surrounding management options during pregnancy, 
and clinicians when counselling patients. However, we do not expect this to have made a 
difference to the principal findings of no benefit from different treatments in a cervical surgery 
cohort. We were further limited by the population demographics with 96% Caucasian 
patients. This limits the generalisability of our findings to other populations including those 




There are currently no studies comparing the efficacy of interventions to prevent PTB in 
women with previous LLETZ or KCB of the cervix. Our study demonstrated around 18% of 
women with previous cervical surgery and no prior sPTB will develop a short cervix and 
require a preventative intervention during pregnancy. There is no statistically significant 
benefit of cerclage, Arabin pessary or VP in prolonging gestation time in this cohort. 
Progesterone is associated with a decrease in gestation time in women with previous 
cervical surgery and a previous PTB. As a result of the retrospective cohort study design, 
these results should be interpreted with caution due to potential bias due to confounding. 
Further prospective studies, preferably in the form of a multicentre RCT, are required to 
confirm our findings. Our results suggest that the aetiology of PTB or the mechanisms by 
which interventions prevent its occurrence in women with cervical surgery may differ to the 
mechanisms for those with a short cervix and other high-risk cohorts. Therefore, future 
studies should consider cervical surgery participants as a separate cohort to those at high 
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cervix: a systematic review. PROSPERO 2021 CRD42021252327 Available 
from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021252327 
Review question 
What is the efficacy of cerclage, progesterone and pessary in preventing preterm birth in 
women with prior excision of the cervix? 
Searches 
A systematic search of PubMed, Scopus and CINAHL databases will be completed by FP 
using the following keywords; cervical surgery, cervical excision, LLETZ, LEEP, cone biopsy, 
conisation, conization, short cervix, high risk, cerclage, progesterone, 17-OHPC and pessary 
to search within study titles and abstracts. 
 
Restrictions will be made for study type, English language and human studies. 
Types of study to be included 
Randomised controlled trials and observational studies (cohort and case-control) will be 
included in the review. 
Any reviews, editorials, books, letters and conference papers will be excluded. 
Condition or domain being studied 
Existing evidence demonstrates an increased risk of preterm birth in women with prior knife 
cone biopsy or LLETZ procedures to the cervix. Preterm birth is the leading cause of 
neonatal morbidity and mortality worldwide. Intervention is indicated following findings of a 
short cervix on mid-trimester ultrasound screening. Current UK practice includes the use of 
either progesterone, cerclage or Arabin pessary to prevent preterm birth. A 2017 Cochrane 
review studied the use of cerclage for women with a short cervix but concluded there was 
insufficient evidence to compare the efficacy to that of progesterone or pessary. Grabovac et 
al reviewed interventions to prevent preterm birth in women with prior cervical surgery and 
singleton or multiple pregnancies. Due to lacking evidence, this review also could not draw 
conclusions for the use of progesterone or pessary. This systematic review aims to address 






Women with singleton pregnancies that have undergone prior knife cone biopsy or LLETZ 
(large loop excision of the transformation zone) procedures will be included. 
All studies reporting outcomes in only multiple pregnancies will be excluded. 
Intervention(s), exposure(s) 
Eligible treatments include vaginal cerclage, Arabin pessary, vaginal progesterone or 
intramuscular 17-alpha hydroxyprogesterone caproate used during pregnancy. Those that 
received a combination of different interventions will be reviewed as a separate treatment 
group. 
Comparator(s)/control 
• Comparison will be made to women that received another intervention. 
• Comparison will be made to women that received no intervention. 
• Comparison will be made to women that received placebo. 
Main outcome(s) 
Primary outcomes are preterm birth <34 and <37 weeks. 
Additional outcome(s) 
Secondary outcome measures include; preterm birth <32, <28 and <24 weeks, PPROM, 
onset and mode of delivery, livebirth/stillbirth, neonatal death, NICU admission, ventilatory 
support, use of surfactant, respiratory distress syndrome, bronchopulmonary dysplasia, 
intraventricular haemorrhage, periventricular leukomalacia, sepsis, maternal mortality/harm, 
side effects and adverse events. 
Data extraction (selection and coding) 
The papers retrieved during the searches will be screened for inclusion by two independent 
reviewers using the pre-determined eligibility criteria. 
Disagreements will be resolved by consensus with a third reviewer. 
The first reviewer will complete data collection from studies that meet the eligibility criteria. 
Risk of bias (quality) assessment 
The risk of bias in each included study will be assessed using a modified version of the 
Newcastle-Ottawa Scale for assessing risk of bias by two different reviewers. 
A sensitivity analysis will be performed for high quality trials. 
Strategy for data synthesis 
Aggregate random effects meta-analysis will be performed using RevMan 5. 
Heterogeneity will be assessed using I², where a result of <40% will be considered 
acceptable. 
If data are insufficient quality for analysis, we will provide a narrative summary of the results 
of included studies, structured around the type of intervention, the characteristics of the 
target population, the type of outcome and the content of the intervention. 





If the included studies allow for subgroup analysis, we will assess differential effects based 
on: 
1) Previous LLETZ procedure; 
2) Previous cone biopsy; 
3) Ultrasound-indicated interventions; 
4) History-indicated interventions. 
 
A sensitivity analysis will also be performed for high quality trials. 
 
 
Appendix 2 – Search strategy used for systematic review 
Pubmed  
1. cervical surgery[Title/Abstract] 
2. cervical excision[Title/Abstract] 
3. lletz[Title/Abstract] 
4. leep[Title/Abstract] 
5. cone biopsy[Title/Abstract] 
6. conisation[Title/Abstract] 
7. conization[Title/Abstract] 
8. short cervix[Title/Abstract] 





14. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 
15. #10 OR #11 OR #12 OR #13 
16. #14 AND #15 AND (clinical study[Filter] OR clinical trial[Filter] OR comparative 
study[Filter] OR controlled clinical trial[Filter] OR observational study[Filter] OR 
randomized controlled trial[Filter]) AND (humans[Filter]) AND (english[Filter]) 
Scopus 
1. TITLE-ABS ( cervical AND surgery ) 
2. TITLE-ABS ( cervical AND excision ) 
3. TITLE-ABS ( lletz ) 
4. TITLE-ABS ( leep ) 
5. TITLE-ABS ( cone AND biopsy ) 





7. TITLE-ABS ( conization ) 
8. TITLE-ABS ( short AND cervix ) 
9. TITLE-ABS ( high AND risk ) 
10. TITLE-ABS ( cerclage ) 
11. TITLE-ABS (progesterone ) 
12. TITLE-ABS ( 17-ohpc ) 
13. TITLE-ABS ( pessary ) 
14. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 
15. #10 OR #11 OR #12 OR #13  
16. #14 AND #15 AND ( LIMIT-TO ( DOCTYPE ,  "ar" ) ) AND ( LIMIT-
TO ( EXACTKEYWORD ,  "Human" )  OR  LIMIT-
TO ( EXACTKEYWORD ,  "Humans" ) )  AND  ( LIMIT-TO ( LANGUAGE ,  "English" ) ) 
Cinahl  
S1. TI cervical surgery AND AB cervical surgery 
S2. TI cervical excision AND AB cervical excision 
S3. TI lletz AND AB lletz 
S4. TI leep AND AB leep 
S5. TI cone biopsy AND AB cone biopsy 
S6. TI conisation AND AB conisation 
S7. TI conization AND AB conization 
S8. TI short cervix AND AB short cervix 
S9. TI high risk AND AB high risk 
S10. TI cerclage AND AB cerclage 
S11. TI progesterone AND AB progesterone 
S12. TI 17-ohpc AND AB 17-ohpc 
S13. TI pessary AND AB pessary 
S14. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9  
S15. S10 OR S11 OR S12 OR S13  
S16. S14 AND S15  
 
 
Limiters - English Language, Human 
Publication Type - Clinical Trial, Journal Article, Randomized Controlled Trial 
